NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Diagnostics Advisory Committee – Wednesday 18 September 2024

Artificial intelligence software to help detect fractures in on X-rays in urgent care

The following documents are made available to the Committee:

- **1. Overview**
- **2. Organisation submission from:** The Society of Radiographers

3. Updated External Assessment Report (EAR) – prepared by Peninsula Technology Assessment Group (PenTAG) Note, this report is an updated version to the one issued to stakeholders on 30 August 2024. The updates are listed on page 3a of the report. The update report also includes an addendum on impact of potential implementation costs

4. EAR Consultation comments from Stakeholders and EAG responses.

Artificial intelligence software to help detect fractures in on Xrays in urgent care

GID-HTE10044

Early Value Assessment

Assessment Report Overview

NICE National Institute for
NICE Health and Care Excellence

Background

NICE National Institute for
NICE Health and Care Excellence

Clinical background

Plain film radiography or X-ray is the most common medical imaging approach used to detect fractures in urgent care settings. Missed fractures are reported to be the most common diagnostic error in the $ED¹$.

Missed or delayed diagnosis of fractures on radiographs is reported to occur in around 3% to 10% of cases².

Missed fractures can lead to poor patient outcomes and further harms including³ :

- pain and suffering
- loss of function
- need for further or prolonged treatments
- cosmetic deformity
- nerve damage
- prolonged recovery
- death.

NICE

Missed and delayed fracture diagnoses can also have an impact on service delivery, for example:

- increased waiting times
- delays in people being discharged
- people being recalled
- additional medical appointments
- surgical procedures and physiotherapy.

^{1.} [Hussain et al. 2019](https://bmcemergmed.biomedcentral.com/articles/10.1186/s12873-019-0289-3); 2. [Kuo et al. 2022](https://pubs.rsna.org/doi/10.1148/radiol.211785?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed);

^{3.} [NHS resolution report on missed fractures](https://resolution.nhs.uk/wp-content/uploads/2022/03/2-NHS-Resolution-ED-report-Missed-Fractures.pdf)

Unmet need

- The [radiology get it right first time programme national speciality report](https://gettingitrightfirsttime.co.uk/wp-content/uploads/2020/11/GIRFT-radiology-report.pdf) highlights the increasing demand on radiology services that is not matched by growth in NHS radiology capacity. As a result, following interpretation in urgent care, a definitive diagnosis by a radiology specialists is often delayed.
- X-rays are initially interpreted in the urgent care setting by healthcare professionals who are not radiology specialists and may be inexperienced at interpreting X-rays, potentially leading to missed fractures or unnecessary referrals to fracture clinics prior to a definitive radiology report.
- Other factors that may contribute to missed or delayed diagnosis include busy work environments and frequent distractions, suboptimal image visualisation facilities, and interpretation outside normal working hours.

Purpose of the technology

Artificial intelligence (AI) technologies that can help detect fractures and support healthcare professional interpretation of X-ray images could improve the accuracy of X-ray fracture diagnoses in urgent care settings. This could help reduce:

- the number fractures that are missed before a radiologist or reporting radiographer reviews the X-rays.
- the number of people being recalled to hospital following radiology review
- the risk of further injury or harm to people during the time between interpretation and initial treatment decision in the ED and the radiology report.
- the burden of unnecessary referrals to virtual fracture clinics.

Ionising radiation (medical exposure) regulations (IRMER)¹ state that clinical evaluation of X-rays requires a trained person. Therefore, AI technologies currently can't be used autonomously without human interpretation.

1. IR(ME)R: Implications for clinical practice in diagnostic imaging, interventional radiology and diagnostic nuclear medicine (2020)

Target condition and current practice

- Fracture assessment and diagnosis typically involves triage where an ED nurse, Advanced Clinical Practitioner (ACP) or ED doctor will carry out an initial assessment before requesting imaging.
- X-rays are usually the first line imaging approach for non-complex fractures and are performed by a diagnostic radiographer.
- Multiple treatment options are available for fractures including surgical and non-surgical approaches depending on the type of fracture.

See the *final scope* for further details.

Variation in practice

- NICE guideline on non-complex fractures ([NG38\)](https://www.nice.org.uk/guidance/ng38)¹) recommends that a radiologist, radiographer or other trained reporter should review X-rays and provide a definitive report before the injured person is discharged (hot reporting). Clinical experts explained that in practice this is not always possible and reporting delays can occur ranging from days to weeks.
- Clinical experts said that X-rays are not usually prioritised for radiology reporting, with most centres operating a first-in, first-out system.
- There may be variations in the staff groups that would be involved in diagnosing fractures for people that attend an urgent care settings out of hours
- Different imaging types may be used for some suspected fractures, depending on centre resources and capacity:
	- [NG38](https://www.nice.org.uk/guidance/ng38)¹ recommends that MRI should be considered for first-line imaging for suspected scaphoid fractures
	- [CG124](https://www.nice.org.uk/guidance/cg124)² recommends offering MRI or CT if a hip fracture is suspected despite no fracture being detected on X-ray

7

Overview of medical imaging pathway for non-complex fractures

8

ENP: emergency nurse practitioner, ACP: Advanced clinical practitioner, ED: emergency department, HCP: healthcare professional

Interventions

Decision problem (1)

- Does the use of software with artificial intelligence (AI) derived algorithms for analysing X-ray images to detect suspected fractures have the potential to be clinically and cost-effective to the NHS?
- Does the software have the potential to address an unmet need in the NHS?

For further details see the [final scope](https://www.nice.org.uk/guidance/indevelopment/gid-hte10044/documents) and the EAG's [final protocol](https://www.nice.org.uk/guidance/indevelopment/gid-hte10044/documents).

Decision problem (2)

Outcomes Intermediate measures for consideration may include:

- Measures of diagnostic accuracy to detect fractures
- Accuracy when used by different healthcare professionals
- Diagnostic confidence
- Healthcare professional X-ray reading time
- Time to diagnosis or time to X-ray definitive radiology report
- Time spent in the emergency department, urgent treatment centre or minor injuries unit
- Time to treatment
- Proportion of people that need further imaging
- Number of missed fractures
- Rate of missed fracture-related further injury
- Number of people recalled following radiology review
- Number of treatments
- Number of hospital appointment/visits including referrals to fracture clinics and orthopaedics

11

- Number of hospital admissions and length of stay in hospital
- Number of further imaging events required
- Failure rate or rate of inconclusive AI reports
- Healthcare professional user acceptability of AI tools for detecting fractures

Clinical effectiveness

NICE National Institute for
NICE Health and Care Excellence

Clinical effectiveness: evidence base

- 16 studies were identified that met the inclusion criteria for the clinical effectiveness review.
	- o 8 studies evaluated BoneView
	- o 5 studies evaluated RBfracture
	- o 1 study each for Rayvolve and TechCare Alert
	- o No studies were found for qMSK
	- o One study (Bousson et al. 2023) was a head-to-head comparison of assisted reading using 3 technologies: BoneView, Rayvolve and TechCare Alert.

Full details of the included studies are in table 2, pages 26 to 29 in the EAR.

Evidence base: outcomes

- Sensitivity, specificity, and contingency tables were reported or calculable for all studies.
- Diagnostic accuracy that was reported per patient (rather than per fracture or per scan) was prioritised by the EAG for inclusion in the review. This is because most studies reported data in this way and because these data were most relevant to the economic analysis.
- PPV and NPV were either not reported or were not extracted for case-control studies.
- Full details of outcomes reported in the included studies are presented in table 5 (page 50) in the EAR.

Evidence base: impact of study design

- The EAG said that consecutive and random sampling study designs are generally more robust for diagnostic evaluation, as they more closely represent the prevalence of the target condition that would be seen in clinical practice.
- Six studies^{1–6} included consecutive cases presenting to participating centres during the study period.
- One study⁷ included a random selection of cases from a database of patients who presented with a suspected fracture.
- Nine studies $8-16$ used a case-control design.
- Most studies were retrospective with only $2^{3,5}$ using a prospective design.

See section 4.2.1 (page 30) of the EAR for further details.

Evidence base limitations

- None of the included studies were set in the UK.
	- The EAG stated that it is uncertain how applicable data from other countries is to the target settings
- Diagnostic accuracy of the index test and technologies would be expected to vary according to both case mix and reader experience.
- Most studies did not specify the version of the technology or training received
- Washout period between reading ranged between no washout to 3 months

16

- Where the reference standard was based on limited access to information about the patient and injury, the EAG considered there to be an increased risk of incorrect judgements
- Reference standard used in 3 studies¹⁻³ included the results of the AI technology, and in one study⁴ it was unclear whether this was the case.

1. Canoni-Meynet et al. 2022; 2. Bousson et al. 2023; 3. Yogendra [unpublished]; 4. Oppenheimer et al. 2023. For more detail see section 4.2.1 in EAR

Quality appraisal of included studies

- Three studies¹⁻³ were considered to be the most appropriate for sensitivity and specificity estimates.
- Only 1 study⁴ was considered to be appropriate for estimates of prevalence, NPV and PPV. However, this study only included wrist fractures.
- None of the included evidence was considered to be robust for all diagnostic outcomes.
- The EAG did not do a formal quality assessment of the included studies. An overview of how quality considerations influenced the interpretation of diagnostic evidence and the selection of evidence to inform the economic analysis is shown in Table 6 (pages 51 to 52) in the EAR.

See slides 20, 23, 25 and 27 for further details on the quality assessment of the key studies.

Evidence base: key studies

The EAG investigated whether it was possible to conduct a meta-analysis of data from the included studies:

• A meta-analysis to identify a pooled estimate of sensitivity and specificity for a particular technology was not feasible due to unexplained heterogeneity in the results of the studies.

Due to the evidence limitations and lack of meta-analysis, the EAG identified key studies that provided the best quality evidence available to inform the economic analysis.

The EAG prioritised studies which:

- did not include the AI reports in the reference standard
- reported results for both AI assisted and unassisted readers
- had relatively large sample sizes
- were peer-reviewed.

The key studies for each technology were:

- BoneView: Duron et al. 2021 (for adults) and Nguyen et al. 2022 (for children and young adults)
- RBfracture: Bachmann et al. 2024 (adults and children)
- Rayvolve: Fu et al. 2024 and Bousson et al. 2023
- TechCare Alert: Suite 2020* and Bousson et al. 2023.

18 *Suite 2020 was not presented in a peer-reviewed publication. Evidence for this technology was therefore of poorer quality than the studies listed above.

Diagnostic accuracy: issues

- The EAG grouped results according to the description of reader experience and seniority described in the publications. As all included studies were based outside of the UK, it was unclear how relevant the staff grades were to the intended staff groups in the NHS. Three reader groupings were used:
	- Less experienced,
	- mixed or unclear staff level, and
	- senior and highly experienced staff.
- In general, readers with greater seniority and expertise at reading X-rays were associated with more accurate unassisted diagnosis estimates, but this was not always the case. The EAG noted that, as this lacks face validity, these results should be interpreted with caution when pooled for the evidence synthesis.

Key studies: Boneview

Diagnostic accuracy: Boneview (1)

Mixed fracture and age groups

Hand and wrist

Further details including results for other staff experience groups are shown in tables 7 and 9 in the EAR.

NICE

Diagnostic accuracy: Boneview (2)

Foot and ankle

Salter-Harris

Further details including results for other staff experience groups are shown in tables 7 and 9 in the EAR.

NICE

Key studies: RBfracture

²³ See tables 2, 3 and 4 in the EAR for full details. NPV, negative predictive value; PPV, positive predictive value

Diagnostic accuracy: RBfracture

Mixed fracture and age groups

Further details including results for other staff experience groups are shown in tables 7 and 9 in the EAR.

Key studies: Rayvolve

25 See tables 2, 3 and 4 in the EAR for full details. NPV, negative predictive value; PPV, positive predictive value

Diagnostic accuracy: Rayvolve

Further details including results for other staff experience groups are shown in tables 7 and 9 in the EAR.

NICE

Key studies: TechCare Alert

Diagnostic accuracy: TechCare Alert

Further details including results for other staff experience groups are shown in tables 7 and 9 in the EAR.

NICE

Diagnostic accuracy: Paediatric subgroup

Two of the key studies^{1,2} reported diagnostic accuracy data in children and young people. One evaluated Boneview and was in children and young people only¹ and 1 study evaluated RBfracture and reported paediatric subgroup data².

Further details including results for other staff experience groups are shown in table 8 in the EAR.

Evidence synthesis (1)

The EAG used 2 approaches to synthesise the evidence base:

- 1. Data from included studies within each grouping was summarised using median and ranges (see slides 31 to 37)
- 2. Conducted a narrative synthesis to identify patterns in the data that could be used to inform an understanding about the potential value of the technology for assisting in the diagnosis of fractures.
- Synthesised data from the included studies was split by fracture type (all fractures and specific fracture sites).
- The EAG said that the results provide an insight into potential patterns across the dataset, rather than precise diagnostic accuracy data for the technologies.

For further details see section 5.2 in the EAR

Evidence synthesis (2): unassisted diagnostic accuracy

- The EAG noted that the rate of missed fractures for clinicians reading X-rays without AI assistance was high across studies, even for senior and expert readers.
- Sensitivity and specificity each varied significantly across studies though, in general, unassisted readers had higher specificity, resulting in a high median rate of missed fractures.
- Accuracy of unassisted readers for detecting hip fractures was high.
- Sensitivity for detecting hand/wrist and foot/ankle fractures was lower than the mixed fracture analyses, and there was variability in specificity for detecting hand/wrist fractures across studies.
- There was poorer sensitivity for identifying non-obvious fractures across all readers. **NICE**

Boneview accuracy across studies (all fractures)

The EAG noted that BoneView showed high sensitivity and specificity, irrespective of the reader group. However, median numbers of missed fractures (all fracture analyses) exceeded 15% for all readers except the senior and expert reader group. In general, BoneView had improved specificity relative to sensitivity, with fewer false positives than missed fractures.

Boneview accuracy across studies (by fracture site)

Sensitivity for non-obvious fractures was improved compared to the results for unassisted, although the rate of missed fractures and false positives was still high in the less experienced staff group (43.8% and 21.1%).

NICE

RBfracture accuracy across studies

The EAG noted that RBfracture showed good sensitivity and specificity across all studies, however rates of false positives across

reader experience levels were similar to unassisted readers.

Rayvolve accuracy across studies

Two studies evaluated Rayvolve, both of which reported high sensitivity but poor specificity, particularly for hand/wrist and foot/ankle fractures. The EAG considered this was a feature of the technology algorithm, to prioritise missed fractures over false positives. Accordingly, specificity was comparable with unassisted diagnosis, while sensitivity was generally improved.
TechCare Alert accuracy across studies

Two studies evaluated TechCare Alert, with no crossover in the reader groupings. Both reported high sensitivity and specificity estimates.

Diagnostic accuracy across studies in paediatric participants (all fractures)

No diagnostic accuracy data in children and young people was available in a less experienced reader group only. In mixed or unclear experience readers, BoneView and RBfracture improved median sensitivity for detecting fractures, though made no clear difference to specificity.

NICE

Subgroup evidence availability

- \bullet Five¹⁻⁵ studies included a mix of adults, children and young people, with 2^{3,4} reporting subgroup data specifically in children and young people.
- Two 6.7 studies were conducted only in children and young people
- No studies reported frailty measures for participants and no studies reported information on the number of participants with diseases that affect bone health.

X-ray reading time

Data on X-ray reading time with and without AI assistance was available for 3 technologies: BoneView (4 studies), RBfracture (2 studies) and Rayvolve (1 study).

- There were no noticeable differences in reading time across the staff groupings.
- BoneView and Rayvolve were both associated with a reduction in X-ray reading times across all staff groups:
	- BoneView 2.6 to 13 seconds per X-ray
	- Rayvolve 7 seconds per X-ray
- One study reported that RBfracture was associated with
- There were large standard deviations around reading time in all studies, which may be due in part to the reading time varying widely by type and complexity of the fracture.
- The EAG was also concerned about the reliability of how reading time would be measured in studies, and potential differences in the way this was defined and recorded between studies.

39 Reading times for all fracture types by staff experience group are shown in table 10 (page 77) in the EAR

Summary of clinical effectiveness evidence

- There was a trend (across technologies and reader groups) for the AI technologies to improve sensitivity with little improvement in specificity
- Differences in accuracy between the technologies are uncertain due to limited evidence and variation in study designs
- Very few studies are specific to emergency care settings and all were associated with limitations due to risk of bias or uncertain generalisability.
- Fractures were still missed with AI assisted interpretation in all reader groups. Reported rates of missed fractures across all studies and fracture types ranged from 1.8% to 43.8%
- In children and young people, 2 key studies reported improved sensitivity but little improvement to specificity
- No evidence for people who are frail or with conditions that affect bone health and long-term recovery

Summary of key diagnostic accuracy results

Boneview:

- Key studies reported improvements in sensitivity and specificity, across all fracture types.
- Improved sensitivity and to a lesser extent specificity, irrespective of the reader group
- In general, BoneView had improved specificity relative to sensitivity, with fewer false positives than missed fractures.

RBfracture:

- Key study reported improved sensitivity and specificity in the less experienced reader group when using RBfracture to help diagnose mixed fractures
- Showed high sensitivity and specificity across all studies, however rates of false positives across reader experience levels were similar to unassisted readers

Rayvolve:

- Key study reported improved sensitivity in less experienced and mixed reader groups. Specificity (where reported) was similar with or without AI assistance.
- Across all studies poor specificity, particularly for hand/wrist and foot/ankle fractures. Specificity was comparable with unassisted diagnosis, while sensitivity was generally improved

Techcare Alert:

• In key studies and across all studies, Techcare Alert showed high sensitivity and specificity**NICF**

Ongoing studies and evidence

Economic evaluation

Review of the economic literature (1)

See section 4.1 of the EAR for details of the evidence searches used to identify relevant economic studies.

- No economic evaluations of AI to detect fractures were identified
- The EAG identified 4 studies that were used to inform health state costs and utilities:
	- **1. Rua et al. (2020)** used to inform modelling of hand/wrist fractures
	- **2. Nwankwo et al. (2022)** used to inform modelling of foot/ankle fractures
	- **3. Low et al. (2021)** used to inform modelling of hip fractures
	- 4. Judge et al. (2016) used to inform modelling of hip fractures

Economic model (1)

- The EAG developed a de novo model to explore the potential cost-effectiveness of AI-assisted diagnosis compared with unassisted diagnosis of fractures in an urgent care setting from the perspective of the NHS and Personal Social Services.
- The EAG divided the analysis into 3 separate fracture sites, focussing on fractures of the
	- wrist and hand
	- ankle and foot
	- hip
- These 3 sites were considered to potentially gain the greatest benefit from AI-assisted diagnosis.
- Separate models were used because costs and consequences of these fractures differed substantially

Outputs of these were then weighted based on the fracture case mix of a typical urgent care setting to estimate the overall costeffectiveness of AI-assisted diagnosis.

Economic model (2)

- The EAG said that the model described represents a rapid overview of the likely costs and consequences associated with use of AI algorithms to assist in the diagnosis of fracture, and unassisted diagnosis, in an urgent care setting.
- The purpose of this analysis was to explore whether there was a plausible case for any of the technologies to represent value for money for the NHS / taxpayer and to identify where further evidence generation may improve the certainty of the results.

Economic model structure

T+ = conditional probability of a positive result from review of X-ray (in branch shown this is sensitivity). Model allows for 1 or 2 reviews.

Base case prevalence, sensitivity and specificity

Two of the studies^{1,2} identified in the review were selected as sources for prevalence and sensitivity and specificity of each diagnostic strategy:

Bousson et al. (2023) provided a directly comparison between BoneView, Rayvolve and TechCare Alert. Data were disaggregated by foot, ankle and hand (but not hip). For the base case, the EAG estimated a mean sensitivity and specificity for foot and ankle, assumed hand applied equally to wrist, and assumed the sensitivity and specificity of hip fracture diagnosis was equal to that for 'all fractures'.

Bachmann et al. (2024) compared RBfracture assisted to unassisted diagnosis in a wide range of fracture types, reporting results by 'mixed' staff types, ED trainees and trauma care nurses. This was used as the source study for RBfracture and unassisted diagnosis. As data were not disaggregated by fracture type, the base case assumed the same sensitivity and specificity for all fracture types for RBfracture and unassisted diagnosis.

Base case prevalence, sensitivity and specificity

NICE

Modelling key assumptions

Model specific assumptions are described separately (see slides 51 to 53)

Foot and ankle fractures: Costs and QALYs

The time horizon for the foot and ankle model was 12 months.

The utility associated with ankle/foot fracture (0.225) was considered to lack face validity for a soft tissue injury and so was explored

in a scenario analysis (see slide 56)

NICE

Hand and wrist fractures: Costs and QALYs

The time horizon for the hand and wrist model was 6 months.

Hip fractures: Costs and QALYs

The hip model had a lifetime time horizon.

Overall impact of AI-assisted diagnosis in an urgent care setting

- Clinical advice to the EAG was that for 2022-23, there were approximately 25.3 million ED attendances in England and that fractures typically account for 2-4%
- Clinical opinion on the prevalence by fracture type was that around 12.5% are ankle, 7.5% wrist and 12.5% hip
- EAG used these proportions to estimate the overall impact of diagnosis in an urgent care setting with 350–400 daily attendances, which results in 1,334 attendances for fracture a year

Base case distribution of fracture types (annual)

Costs

- In the base case the cost per scan was based on 1,334 scans per year
- The cost of the index presentation and X-ray was excluded from the analysis as it is common to all arms
- For health states in which additional presentations occur (false negatives), a mean cost of £149.04 was used
- Cost per scan for TechCare Alert

Scenario analyses

Base case results: Overall

- Overall, with the exception of Rayvolve, the AI-assisted diagnostic algorithms were associated with a positive incremental net health benefit compared with unassisted diagnosis at £20,000 and £30,000 thresholds.
- 95% confidence intervals in most cases crossed zero, both for all separate fracture sites/types and when considered together.

57

• Due to data limitations, the EAG advised against direct comparisons between different AI algorithms

See table 45 in the EAR for further details including INHB30k results. Abbreviations: CI, confidence interval; INHB20k, incremental net health benefit at willingness to pay threshold of £20k; QALY, Quality Adjusted Life Year

Base case results: Ankle and foot

58

- There was minimal difference in QALYs between the different technologies and unassisted diagnosis.
- Costs varied more than QALYs for ankle and foot fractures
- Only Rayvolve had a significantly different cost to unassisted reads

See table 42 in the EAR for further details including INHB30k results. Abbreviations: CI, confidence interval; INHB20k, incremental net health benefit at willingness to pay threshold of £20k; QALY, Quality Adjusted Life Year

Base case results: Wrist and hand

• There was minimal difference in costs and QALYs between the different technologies and unassisted reads.

See table 43 in the EAR for further details including INHB30k results. Abbreviations: CI, confidence interval; INHB20k, incremental net health benefit at willingness to pay threshold of £20k; QALY, Quality Adjusted Life Year

Base case results: Hip

- There was very little difference in QALYs between assisted and unassisted reads for hip fracture.
- Rayvolve had a significantly higher cost than unassisted reads.

See table 44 in the EAR for further details including INHB30k results. Abbreviations: CI, confidence interval; INHB20k, incremental net health benefit at willingness to pay threshold of £20k; QALY, Quality Adjusted Life Year

Base case results: maximum economically justified price

- The EAG also calculated the maximum economically justifiable price for each of the technologies. This is the maximum cost per scan that would still result in a technology being cost effective with an ICER of £20k or £30k per QALY gained.
- The minimum economically justified prices were generally higher than the per-scan prices proposed by the companies and used in the base case model (see slide 55).

61

Scenarios results

- Only scenarios adjusting diagnostic accuracy had a large impact on model results.
- Other scenarios including low and high volume based pricing, reduction in reading times, higher utility values for true negative ankle/foot fractures, use across all fractures, and adding a second read did not affect the model results.
- Full scenario analysis results are presented in table 48 (pages 117 to 120) in the EAR.

NICE

Optimistic diagnostic accuracy

CI, confidence interval; INHB20k, incremental net health benefit at willingness to pay threshold of £20k; QALY, Quality Adjusted Life Year

Summary of economic evidence

- Early economic modelling suggests that most of the AI technologies considered have the potential to be cost effective.
- Most of the AI technologies had a positive INHB at £20k and £30k thresholds although 95% confidence intervals in most cases crossed zero
- The lower specificity of Rayvolve leads to higher costs dues to more people being referred for further investigation
- EAG noted that the potential cost-effectiveness appeared to be driven by reductions in costs rather than a gain in QALYs
- EAG cautions against using this analysis to compare one AI algorithm against another due to data limitations

Evidence gaps and research recommendations

Key evidence gaps identified by the EAG included:

- Lack of prospective, consecutively sampled, comparative studies based in clinical settings comparable to the NHS urgent care setting, with staff/reader groups that would typically perform the initial interpretation.
- Studies designed to explore changes in outcomes according to key factors that would inform use of the technology, such as reader experience, fracture case mix, and determinants of patient outcomes, such as patient age, frailty, and prevalence of health conditions affecting bone health.
- Longer term costs and consequences of missed fracture diagnoses
- System level outcomes such as number of referrals to virtual fracture clinics or time spent in ED

Health Tech Programme

Artificial intelligence software to help detect fractures in the emergency department (provisional title)

Professional organisation submission

Thank you for agreeing to give us your organisation's views on this technology and its possible use in the NHS.

You can provide a unique perspective on the technology in the context of current clinical practice that is not typically available from the published literature.

To help you give your views, please use this questionnaire. You do not have to answer every question – they are prompts to guide you. The text boxes will expand as you type.

Information on completing this submission

- Please do not embed documents (such as a PDF) in a submission because this may lead to the information being mislaid or make the submission unreadable
- We are committed to meeting the requirements of copyright legislation. If you intend to include **journal articles** in your submission you must have copyright clearance for these articles. We can accept journal articles in NICE Docs.
- Your response should not be longer than 13 pages.

Any confidential information provided should be underlined and highlighted. Please underline all confidential information, and separately highlight information that is 'commercial in confidence' in blue and all that is 'academic in confidence' in yellow.

The aim of treatment for this condition

What is the expected place of the technology in current practice?

The use of the technology

Sources of evidence

Equality

Key messages

Thank you for your time.

Please log in to your NICE Docs account to upload your completed submission.

Your privacy

The information that you provide on this form will be used to contact you about the topic above.

Please select YES if you would like to receive information about other NICE topics - YES

For more information about how we process your personal data please see our [privacy notice](https://www.nice.org.uk/privacy-notice).

Artificial intelligence software to help detect fractures on X-rays in urgent care: An Early Value Assessment EAG assessment report (Post-FAC)

Author contributions

This report should be referenced as follows: Farmer, Coelho, Muthukumar, Robinson, Meertens, Ukoumunne, Santo, Gale, Evans, Evans, Melendez-Torres, Wilson. Artificial intelligence software to help detect fractures on X-rays in urgent care: An Early Value Assessment. EAG assessment report. Peninsula Technology Assessment Group (PenTAG), 2024.

The views expressed in this report are those of the authors and not necessarily those of the NIHR Evidence Synthesis Programme. Any errors are the responsibility of the authors. Any errors are the responsibility of the authors. Copyright 2024, PenTAG, University of Exeter.

External Assessment Report: Changes after stakeholder consultation

Section Description of change 4.2.1 Corrected 'unassisted' to 'assisted' 4.2.1 Clarified description of Fu 2024 study design Table 9 Corrected unassisted diagnostic accuracy for Nguyen 2022 Table 11 Corrected specificity for "Unassisted, mixed or unclear staff, hand/wrist" Table 21 Standard deviations removed for Durations 1 and 2 8.3.4 Costs specified in text for False Negatives Table 22 Added new table showing calculation of QALYs for false negative ankle/foot fractures Tables 24, 26, 28, 30 Costs for hand/wrist corrected Table 32 Costs for secondary prevention care following hip fracture corrected Table 35 Costs for false negative hip fractures corrected Tables 37, 39 Costs for RBFracture corrected [redacted] Tables 42 – 48 Outputs of model updated following amends as described above [some redacted] 8.5 Updated text in response to consultee comment Appendix D New scenario added to investigate impact of set-up costs.

Editorial corrections not tabulated.

Table of Contents

List of tables

Executive Summary

Background and objectives

Plain film radiography or X-ray is the most common medical imaging approach used to detect fractures in urgent care settings, including the emergency department (ED), urgent treatment centre (UTC), and minor injuries units (MIU). X-rays are typically read in urgent care settings by healthcare professionals who are not radiology specialists or are inexperienced at interpreting X-rays, which may increase the likelihood of errors in decision-making, particularly in busy healthcare centres when staff are under significant pressure. Reduced staff numbers, such as outside normal working hours, may also influence the risk of errors in diagnosis. A definitive diagnosis of the injury will be produced by a consultant radiologist or reporting radiographer, although there may be a delay before this is available, meaning that this may arrive after people have been treated and/or discharged from urgent care. Delays vary across settings, and may be longer for children due to availability of specialist in paediatrics.

Artificial intelligence (AI) algorithms have been developed to support clinicians in diagnosing fractures, with the intention to improve the diagnostic accuracy of clinicians reviewing X-rays. Improving diagnostic accuracy means reducing the number of missed fractures (false negative diagnoses) and the number of people treated for a fracture who don't have one (false positive diagnoses).

The purpose of this rapid early value assessment (EVA) was to identify the existing evidence base for the technology and to assess whether there was a *prima facie* case for the technology to represent a value for money investment for people in the NHS. A rapid evidence review was conducted followed by 'light touch' early economic modelling to explore whether a plausible case could be made for cost-effectiveness at the prices charged by the companies. The approach was not suitable for a definitive assessment of the cost-effectiveness of one AIalgorithm against another, but rather to inform whether or not the NHS should consider adopting the technology whilst further evidence is collected.

Evidence review – clinical and service use outcomes

A broad evidence review was conducted to identify the existing evidence base for clinical, and service outcomes associated with the technology. The review identified 16 studies that evaluated the diagnostic accuracy of the technology as an aid to diagnosing fractures (i.e. when

used to assist reading clinicians, and not as a standalone diagnostic tool). Evidence was available for four of the eligible technologies: BoneView, Rayvolve, RBFracture, and TechCare Alert. None of the included studies were conducted in the UK and all were associated with limitations, including risks of bias and uncertain generalisability to the NHS. Few studies evaluated the technologies when used by clinicians who would typically provide the initial diagnosis in urgent care settings, with most evaluating readers who were clinicians specialising in radiology or amongst a varied of group of clinicians with varying levels of reading experience. Data were reported for a general sample of people with types of fractures that were eligible for consideration by the technologies. Subgroup data were also available for pre-specified fracture subgroups, for children and for 'less obvious' fractures. None of the included studies reported clinical outcomes associated with use of the technology and, aside from the reading time per scan, no service outcomes were reported. As compared to the list of outcomes specified in the NICE scope for this assessment, there was a major gap in the evidence base.

There was unexplained heterogeneity in the results reported across studies. To aid with interpretation of the results, where multiple results were reported by studies according to staff experience, the EAG grouped the data according to reader experience (as described by the included publications). This approach was considered imperfect and did not completely resolve the heterogeneity in the data. The EAG conducted a feasibility assessment to determine if metaanalysis of the data was possible, but where sufficient numbers of studies were available, these were considered too heterogeneous to pool. Notably, clinical advice to the EAG was that the diagnostic accuracy of unassisted readings in the included studies appeared lower than was expected by the EAG's clinical advisors, which adds uncertainty to the generalisability of the evidence base.

Overall, given the limitations in the evidence base and the heterogeneity in the study results, the EAG did not consider that the evidence base was suitable to determine reliable estimates of the diagnostic accuracy of the technologies for assisting in the diagnosis of fractures. However, based on evaluation of the evidence base as a whole and specifically in studies reporting outcomes for clinicians based in emergency care settings, the EAG identified a general trend for the technology to result in an improvement in sensitivity (i.e. a reduction in missed fractures) with no or minimal improvement in specificity (i.e. no change in false positive diagnoses). Use of the technology was still associated with varying levels of missed fractures, however, particularly in 'less obvious' fractures, where the technology was considered to be of most potential value. Further evidence is needed to determine robust evidence for any improvement in sensitivity,

and to establish whether the additional fractures identified would result in meaningful clinical benefits for patients.

Economic evidence and analysis

The evidence review identified no available economic evaluations for the technologies. The EAG constructed a simple decision model to establish whether there was a *prima facie* case for AI-assisted diagnosis to represent a value for money investment for NHS patients. As the longterm costs and outcomes for different fractures were substantially different, the EAG divided the analysis into three decision problems, concerning ankle and foot, wrist and hand, and hip fractures. These were chosen on the basis of availability of data and their different downstream costs and consequences. An overall estimate of the costs and consequences for a typical urgent care setting was estimated based on case mix for the three fracture types, with extension to all fractures considered in scenario analysis.

The decision model was a decision tree incorporating prevalence, sensitivity, specificity and cost per scan for each of the five diagnostic strategies (four AI algorithms and unassisted diagnosis). Estimates of the long-term costs and QALYs accrued from a true and false positive and negative for each fracture type were extracted from the literature. The tree was rolled back to estimate the expected cost and QALYs accrued from each diagnostic strategy. Scenario analyses explored key uncertainties.

Overall, most of the AI-assisted algorithms were associated with a positive incremental net health benefit at willingness to pay thresholds of £20,000 and £30,000 per QALY gained. Due to data limitations, the EAG did not consider the analysis appropriate to compare technologies against each other, although this would be required in a more thorough analysis in future to ensure that the diagnostic accuracy of each algorithm was matched to its price.

The results were mostly robust to the scenario analyses considered with the exception of diagnostic accuracy, where none of the algorithms were associated with a positive incremental net health benefit (compared with unassisted diagnosis) in the pessimistic scenario.

Key points for decision makers

• While a reasonable number of studies have evaluated the diagnostic accuracy of the technology as an aid to the identification of fractures, very few studies are specific to emergency care settings and all were associated with significant limitations due to risk of

bias or uncertain generalisability. The existing evidence base was not sufficient to determine an approximate estimate of the diagnostic accuracy of the technology for its intended use.

- Across the evidence base as a whole, there was a trend for the technology to reduce missed fractures without any change to false positive diagnoses. However, based on the existing evidence, the EAG was unclear whether the additional fractures identified would translate into meaningful benefits for patients. While there are some fractures that, if missed, can result in significant harm to patients, stakeholders to this assessment also considered it plausible that the technology would improve diagnosis of more subtle fractures that may not require a change in management.
- The evidence suggested that use of the technology would not eradicate the risk of missed fractures, meaning it was likely that health services would need to continue to take precautions to avoid the risk of a missed fracture in clinical practice (e.g. precautionary treatment of high risk suspected fractures). This means that use of the technology had an unclear impact on healthcare resource use.
- On average, based on a simple decision model for this EVA, most of the AI algorithms considered represent a positive incremental net health benefit compared with unassisted diagnosis at NICE's conventional threshold of £20,000 to £30,000 per QALY. The evidence base was not sufficient to compare different algorithms against one another.
- Results were mostly robust to scenario analyses with the exception of diagnostic accuracy.

Plain Language Summary

X-rays are the usual method for diagnosing broken bones (fractures) in urgent care settings, including Accident and Emergency (A&E), urgent treatment centres (UTC), and minor injuries units (MIU). Artificial Intelligence (AI) technologies have been developed to assist in identifying fractures on X-rays, and PenTAG was commissioned to conduct an Early Value Assessment (EVA) to provide an initial view about whether licensed AI technologies could be used for fracture detection in urgent care while further evidence is developed.

A search was conducted to identify all of the evidence that had evaluated AI to assist in fracture detection, including published evidence and confidential data from AI companies. The review identified 16 studies that evaluated how accurate AI was when used to assist diagnosis and 5 studies that reported how AI changed the time needed to interpret an X-ray. None of the studies were based within the UK and most were conducted with staff different to those who would normally read X-rays in the NHS. This meant that it was not possible to identify a good estimate for how accurate AI would be if it was used in urgent care. Overall, there appeared to be early signs that AI could help to reduce missed fractures, but further research would be needed to confirm this. No studies were identified that evaluated how using AI affected outcomes for people with a suspected fracture (such as their health and mobility) or how using the AI affected time and costs for the health service (such as the number of repeat appointments needed).

To assess whether AI would be good value for money for the NHS, we developed an economic model that combined information on how well AI diagnoses fractures, the cost of using AI, and information on what happens to a patient once their fracture is correctly – and incorrectly – diagnosed (their quality of life and costs to the NHS). Overall, our findings were that most of the AI technologies appeared to be fairly priced for the estimated benefits. We explored uncertainties related to the data and assumptions in our analysis and found that our conclusions did not change most of the time.

1. DECISION PROBLEM

The decision problem for this assessment is described in the NICE scope and EAG comments and planned assessment methods are included in the protocol.

During its assessment, the EAG made the following minor adjustments to the planned methods outlined in the protocol. These were:

Definition of frailty: None of the included clinical effectiveness evidence reported the proportion of participants who were assessed as being frail, had experienced a frailty fracture, or reported outcomes specific to this group. Though one of the included economic studies (Beaupre 2020) stated that frailty was considered and assessed bone mineral density (BMD) for elderly people when needed, it did not define "frailty" and indicated that only age was used to classify fragility fractures.

To help characterise the prevalence of people with frailty who were included in the evidence, the EAG reported other metrics that were imperfect but approximate indicators of frailty in the sample, where reported. This included the proportion of participants aged ≥80 years and the proportion of injuries due to falls. These indicators were considered to be imperfect, however.

Reference standard: The EAG included evidence from studies that used a reference standard that did not match that described in the NICE scope and review protocol (i.e. definitive report from a consultant radiologist or reporting radiographer). These decisions were taken due to a paucity of high-quality evidence directly relevant to the decision problem and due to uncertainty surrounding the correspondence between staff grades in other healthcare systems compared to consultant radiologists and reporting radiographers in the NHS. Where reference standards were considered to be indirect or flawed in some way, this is highlighted in the report.

Screening and prioritisation of evidence: The review protocol specified that the EAG would prioritise the clinical and economic evidence and outcomes that best addressed the decision problem for this assessment. As there were numerous quality considerations across the available evidence, it was not possible for the EAG to select a group of robust studies for priority inclusion in the review. Accordingly, the EAG included all of the evidence identified that reported diagnostic accuracy data for the included technologies, despite its limitations. As discussed later in the report, the limitations with the evidence means that the EAG did not aim to determine the diagnostic accuracy of the technologies, but rather to provide an overview of the existing

evidence base, initial interpretations from the results from patterns across the data, and recommendations for future research. One study¹ was de-prioritised following identification as it did not report any of the priority outcomes in the protocol. This study assessed healthcare professional user acceptability of AI for the detection of fractures before and following its implementation in a healthcare setting.

Selection of clinical evidence to inform the economic model: While all studies were associated with key limitations in quality, the EAG sought to select estimates of prevalence, sensitvity and specificity that could be used to inform the economic analysis. The studies with the most robust data – relative to the evidence base as a whole – were selected, though these were nevertheless considered to be unreliable. Studies with the following design features were prioritised for selection of sensitivity and specificity: studies with larger sample sizes; studies reported in peer-reviewed publications; studies that reported results for both AI assisted and unassisted clinicians; and studies that used a reference standard that did not include the results of the AI. Prevalence data selected for use in the economic analysis was derived from studies with: robust sample selection processes; larger samples; and relevant eligibility criteria. As this was an Early Value Assessment, these studies were not subjected to a formal quality appraisal, however key limitations of included studies are discussed within the report.

Information sought from companies. The EAG submitted clarification questions to four of the relevant companies (Gleamer, Radiobotics, AZmed, Milvue) on 29th July and companies were asked to return their responses by $7th$ August. An additional round of questions was submitted to one company (Radiobotics) on $5th$ August. These dates were later than scheduled in the protocol to coincide with the completion of evidence selection, at which point the questions could address uncertainties across the identified evidence base.

2. TECHNOLOGIES

A brief overview of the technologies included in the assessment can be found in Table 1. Please see the NICE scope for further details.

Abbreviations: DICOM, Digital Imaging and Communications in Medicine; IFU, instructions for use; RFI, request for information

Source: all information is reproduced from the NICE scope for this assessment unless stated otherwise.

3. CLINICAL CONTEXT

3.1. Care pathway

The care pathway for fractures within emergency settings in the NHS is described in the NICE scope for this assessment. As part of its assessment, the EAG noted the following additional considerations regarding the care pathway for fractures that was relevant to interpreting the evidence and understanding the potential role of AI as an aid to detecting fractures:

- The scope for this assessment was to consider the clinical and cost effectiveness of AI technologies as a diagnostic aid for detecting fractures in emergency settings, including the emergency department (ED), urgent treatment centre (UTC), and minor injuries units (MIU). These settings differ in the care pathways available to people with suspected fractures, for example in the grade of staff who are available to read radiographs and options for further imaging modalities. There may also be differences in the populations who are admitted to each of these settings, for example MIUs rarely assess people with suspected hip fractures, who in general would be referred to an ED, depending on local policy. In general, MIUs will generally receive a higher case mix of people with suspected fractures of the extremities. Variation in the care pathway and the populations treated within each setting will have implications for the potential value of using AI as a decision aid, as the value of AI is likely to vary according to the staff members using the technology, the fractures assessed, and the downstream impacts of AI on other parts of the care pathway. In order to interpret the evidence for AI as a decision aid presented in this report, it will be important to ensure that the evidence most relevant to the target setting is used and any variation between the evidence base and the target setting is considered carefully.
- Clinical experts noted that the care pathway for the assessment and treatment of fractures varies across the UK as each healthcare service develops and follows its own protocols. While there are established guidelines and standards that guide clinical practice, it is common for services to adapt the care pathway to adjust to the staff and resources they have. This means that there are variations in the staff who provide the initial assessment of x-rays, the use of additional imaging modalities, and the length of time until a definitive report is available. As with the importance of the target setting for the technology, the EAG also noted that the generalisability of the evidence for AI in this report to each healthcare service will vary according to local protocols for assessment and management. In addition to the issues discussed in the NICE scope, the EAG also highlight the following considerations:
- \circ While NICE recommends² that a radiologist, radiographer or other trained reporter should provide a definitive report of an X-ray prior to discharge, the EAG was advised that this was very rarely possible and the typical time to a definitive report was between 24 hours and 2 weeks across different services. This is much longer than targets set by NHS England who have suggested, in consultation with The Royal College of Radiologists and The Society of Radiographers³, a 12-hour target to a definitive report of X-rays for outpatients in emergency settings, with the aim that this should be reduced to a 4-hours. This will be very difficult to achieve without major changes to the service.
- \circ The EAG received advice that services also vary in their approach to producing definitive reports, with some centres processing these on a first come, first served basis, while other centres may use alternative strategies, such as only providing a definitive report of X-rays where the initial assessment was negative (i.e. to confirm that a fracture had not been missed).
- \circ A definitive report from a consultant radiologist or reporting radiographer may not always be necessary depending on the reader of the initial X-ray; for example, a consultant hip surgeon may make the initial diagnosis without the need for a further report.
- \circ The EAG was aware that centres may take precautions to reduce the risk of missed fractures, particularly for those fractures that are known to be challenging to detect on X-ray. For example, suspected scaphoid fractures and intra-articular fractures may have long-term consequences for a person's health and mobility if missed, and so the injury may still be treated as a fracture and re-assessed in two weeks. A riskaverse approach may also be taken with more vulnerable patients for whom the potential consequences of a missed fracture would be considered to be greatest (e.g. children, people identified as frail). Such precautionary tactics are associated with a reduced risk of missed fractures but an increased risk of over-treatment, including the need for additional assessments after 2-weeks. This means that the potential value of AI as a decision aid will vary according to whether centres use any precautionary tactics.
- There are variations in the staff that would be involved in diagnosing fractures for people with suspected fractures that present to emergency settings out of hours (weekday evenings after 6pm, overnight, and weekends). During out of hours, some centres may outsource diagnosis of x-rays to centres overseas (i.e. where daytime staff are available due to the

time difference). Clinical experts suggested outsourcing diagnosis may not necessarily be as accurate, though the EAG did not have any data to confirm this. There may also be variations in the types of fractures seen in emergency settings during out of hours, due to variation in the cause of injuries; for example, sports injuries are more prevalent at weekends, while alcohol induced injuries (falls and injuries due to violence) may be more prevalent overnight. The EAG therefore considered it plausible that the potential value of AI as a diagnostic aid may vary according to whether people with suspected injuries were presenting to emergency settings during out of hours services or during weekdays.

• The EAG considered it plausible that the introduction of AI as a decision aid within the NHS may lead to broader changes to the care pathway, which may vary across centres and be challenging to predict. For example, centres that use AI may alter the staff that are required to provide the initial assessment, may change their practices for ordering and timing the definitive report, and may alter their use of precautionary tactics. Further consideration of issues related to the introduction of AI within a healthcare setting as discussed in Section 3.2.

3.2. Considerations for implementing AI as a diagnostic aid in clinical practice

• As discussed in the review protocol, the EAG received advice that AI would likely be valuable for use as a decision aid in a select group of fractures only, such as those that are challenging to diagnose on X-ray during the initial review and where the consequences for a missed fracture are greatest. However, the EAG was uncertain to what extent the technologies could be targeted towards specific fracture sites only or whether, once implemented, the technology would provide an analysis of all X-rays that are entered into the radiology picture archiving and communication systems (PACS). Information provided by the companies involved in this assessment was that services are charged on a fee for scan basis, with some offering volume-based discounts, meaning that the cost of the technology would vary considerably according to whether the technology is used for some or all suspected fractures. If a service chose to target the technology towards specific fracture types and locations, the EAG was uncertain how feasible this would be to implement in practice, for example whether the technology could be specified to not produce an analysis of certain body locations (as is the case for body locations not covered by the technology) or whether the treating clinician would need to choose to activate the technology for every exam. Expert advice to the EAG was that either approach could be feasible, with the

selective use of the technology ensuring that the technology was only used in the minority of circumstances where additional review was beneficial. Cost implications for the technology will vary according to the way in which the technology is implemented.

- The EAG considered that the successful integration of the technology with Radiology picture archiving and communication systems (PACS), and the perceived ease and acceptability of this, would be important for considering the potential value of the technology. This may include consideration of the effort required to produce a result, the notifications used, and the presentation of the findings. The EAG also considered that, were the technology used, in future it may be required to sit alongside other AI technologies analysing the same images for other anomalies. The EAG was uncertain to what extent the technologies already have this functionality but were aware that other technologies for analysing X-rays for other abnormalities are available. 4
- The EAG considered it plausible that the successful integration of the technology and the extent to which staff have confidence in it may influence the way it's used in clinical practice and, therefore, its potential value for the service. For example, where there are discrepancies in the result given by the technology and clinical judgement, staff confidence in the technology may determine which result they choose to prioritise in the final decision. The EAG received advice from clinical experts that confidence in the technology may vary according to staff grade, in that more junior staff may be more likely to place greater weight on the result from the AI. The EAG was also advised that over-confidence in the AI could have negative consequences; for example, staff may rely on the AI diagnosis during busy periods.
- Clinical advice to the EAG was that the optimum order of use would be for the reader to form a judgement about the X-ray without use of the technology, and only then consult the results provided by the technology. This was partly to avoid over-reliance on the technology, with another benefit being to reduce the risk that readers become less skilled in reading Xrays over time, with potential knock-on consequences (for example, were the technology to not be available in the future). Were the technology to be used in this order, this would increase the reporting time required for X-rays, with potential knock-on consequences for the service.
- The algorithm within AI technologies used for detecting fractures specifies the threshold at which an identified anomaly is defined as a fracture or not, i.e. the level of confidence required for the technology to return a positive result. Depending on the threshold used, this may favour sensitivity or specificity of the technology, according to whether the threshold is

selected to prioritise to avoid missed fractures or false positives. The EAG noted the following considerations on this topic:

- \circ Generally speaking, the preferred threshold may vary according to the fracture being assessed or the needs of the patient. For example, a lower confidence threshold may be chosen for scaphoid fractures when there are significant consequences to the patient of a missed fracture. The EAG was uncertain whether it was possible for the operator to adjust the threshold used by the technology according to the fracture being assessed or whether this changed manually. Based on the information received, the EAG considered it more plausible that the same threshold was used for all fractures. As a consequence, the EAG considered it important that instructions and training for operators encourages the use of clinical judgement to interpret binary responses from technologies.
- \circ Some technologies, particularly more recent versions, include a note about the confidence of the result, such as by using a boundary box around the identified anomaly. The EAG considered that confidence metrics may be interpreted differently across users, although this was something that it was not possible to evaluate within this EVA.
- \circ There is no clear label or metric to identify the threshold used by the technologies during the published evaluations (for example, there is no apparent scale from which to report the threshold used and compare this across studies and different technologies). This makes it difficult to evaluate the performance of different thresholds, and it was also not clear to the EAG when studies of the same technology were using the same or different thresholds. As the sensitivity and specificity of the technology for detecting fractures will vary according to the threshold used, this creates significant uncertainty in the generalisability of the evidence base to clinical practice.
- AI technologies may be updated over time to refine and improve the technology. These iterative updates may lead to dynamic changes to the cost effectiveness of the technology and it was not clear to what extent NICE or local services could monitor this. Expert advice to the EAG was that frequent updates to the technology may be challenging for UK bodies to appraise, and it may be that an approved AI technology would not be expected to undergo update except to correct any defects or safety considerations.

• The EAG was unclear about any legal or ethical implications around using the technology within the NHS. For example, how the introduction of the technology would affect liability considerations for missed fractures discussed in the NICE scope.

3.3. Equality issues

Equality considerations for this assessment were noted in the NICE Scope. Further to these, the EAG identified a paucity of evidence for particularly populations who may be more vulnerable to missed fractures and over-treatment, including people with frailty and those with health conditions that affect their bone health and long-term recovery.

4. CLINICAL, SERVICE AND TECHNOLOGICAL EVIDENCE SELECTION

4.1. Evidence search strategies and study selection

The search strategies are presented in Appendix A and PRISMA diagram for the evidence selection is presented in Appendix B.

Searches were carried out in late June and early July 2024. The search strategies used relevant search terms for artificial intelligence, X-ray and different fracture types; each of these subjects comprised a combination of indexed keywords (e.g., Medical Subject Headings, MeSH) and free-text terms appearing in the titles and/or abstracts of database records. Searches were translated and adapted according to the configuration of each database. No date, language or publication status (published, unpublished, in-press, and in-progress) limits were applied. Searches for clinical and service outcomes and cost-effectiveness were combined and carried out in one search strategy.

Following deduplication, a total of 1,341 records of potentially relevant evidence on clinical and/or cost effectiveness were retrieved. Databases searched were Medline (including Medline in Process), Embase, Cochrane, Web of Science, CEA Registry and HERC. Additional trial registries searched were Clinicaltrials.gov (NLM) and ICTRP (WHO). The websites of the individual companies were searched; NICE and SIGN websites were searched for related guidelines; MAUDE and MHRA were searched for adverse events data. In addition, we scanned the reference lists for the Kuo 2022^5 and Pauling 2024^6 systematic reviews.

During study screening, the EAG identified several studies where the technology evaluated was unclear or where it was unclear whether the technology was evaluated as a standalone technology or with the interpretation of a clinician. In these cases, the EAG sought advice from three of the companies included in this assessment (Gleamer, Milvue, and AZmed) where they were stated to have sponsored the study and/or where staff from their companies were listed as authors. The EAG did not receive a response from Milvue or AZmed during its assessment, and therefore the studies queried were not included in the review. Following a response from Gleamer, one study was included in the assessment and two studies were excluded. Additional queries about included studies were also sent to companies (see Section 7) for details, which resulted in the merging of two studies: Radiobotics 2021⁷ and Bonde [unpublished]. The former of these was a published document with little reported data (though following a request from the EAG the company, Radiobotics, provided additional data) and the latter was a full manuscript in

preparation that reported data for a subgroup of participants in one of the included countries. A full list of exclusions is provided in Appendix C.

4.2. Included and excluded studies

A total of 1,343 titles and abstracts were screened, 209 full-text publications were reviewed, and 16 studies (17 documents) met the review inclusion criteria. The included studies are summarised in Table 2.

One study included in the review (Bousson 2023 δ) conducted a head-to-head comparison of assisted reading using three technologies: BoneView, Rayvolve and TechCare Alert (please note that the study referred to TechCare Alert as 'SmartUrgences', which is an umbrella name for AI technologies developed by the same manufacturer. For pragmatic purposes, the EAG assumed that these were the same technology). The majority of other studies included in the review evaluated readings assisted with either BoneView or RBFracture.

A breakdown of the number of studies evaluating each technology is as follows:

- **BoneView**: nine studies, including two non-comparative studies where BoneView assisted readings were assessed against the reference standard (Cohen 2023 $^{\rm 9}$, Meetschen 2024 $^{\rm 10}$), one head-to-head comparison (Bousson 2023⁸) and five studies that assessed both BoneView-assisted and unassisted readings (Canoni-Meynet 2022¹¹, Dell-Aria 2024¹², Duron 2021¹³, Guermazi 2022¹⁴, Nguyen 2022¹⁵, Oppenheimer 2023¹⁶)
- **RBFracture**: five comparative studies (Bachmann 2024¹⁷, Jørgensen 2023¹⁸, Radiobotics 2021⁷ (also Bonde), Ruitenbeek 2024¹⁹, Yogendra [unpublished]²⁰)
- **Rayvolve**: one comparative study (Fu 2024²¹) and one head-to-head comparison (Bousson 2023⁸)
- **TechCare Alert**: one comparative study (Suite 2020²²) and one head-to-head comparison (Bousson 2023²³)
- **qMSK**: zero studies

Table 2: Overview of included studies with clinical and technological evidence

Abbreviations: CT, computed tomography; DTA, diagnostic test accuracy; MRI, magnetic resonance imaging; NR, not reported; PET, positron emission tomography

4.2.1. Study design and diagnostic tests

Details about the methodological approach used by the included studies are provided in Table 3.

Six studies^{9 11 16 23 24 27} included consecutive cases presenting to participating centres during the study period and one study²¹ included a random selection of cases from a database of patients who presented with a suspected fracture. The remaining nine studies^{7 10 13 14 17 18 20 22 25} used a case-control design to stratify inclusion towards a set fracture prevalence rate (typically 50%, with additional requirements, such as spread of specific fracture types and age groups). Consecutive and random sampling study designs are generally more robust for diagnostic evaluation, as the study samples more closely represent the prevalence of the target condition that would be seen in clinical practice, meaning that prevalence data and PPV and NPV outcomes (each affected by the prevalence rate) will be more reliable. However, as the diagnostic accuracy of X-ray varies according to the fracture location, even consecutive and random sampling designs may be limited if they do not include a mix of fracture types that is representative of clinical practice (meaning that sensitivity and specificity data may not be generalisable). This issue is discussed further in Section 4.2.1.

The vast majority of studies used a retrospective study design, with only two studies (Oppenheimer 2023¹⁶ and Dell-Aria 2024²⁴) using a prospective design. Retrospective designs are unlikely to be representative of clinical practice for several reasons, including that readers have knowledge that their judgement will not impact upon patient care, readers are less likely to have the same access to support from colleagues, and readers may not dedicate the same length of time and consideration to reading X-rays within these circumstances compared to clinical practice.

None of the included studies were set in the UK, though the majority (12 studies) included sites in Europe, five studies included sites in USA, and one study was set in Asia (Singapore). Based on the information reported in the included studies, it was not clear to the EAG how applicable the study findings were to the decision problem for the assessment; i.e. the target emergency settings of ED, MIU and UTC, and the extent to which readers of index tests and the reference standard were comparable to staff in the target settings. This was a major limitation of the evidence base, since – as noted in the review protocol – the diagnostic accuracy of the index test and technologies would be expected to vary according to both case mix and reader experience. Eight of the included studies $9-11\frac{16\frac{18}{20}22-24\frac{27}{20}}{160}$ were described to be set within a

hospital and/or trauma centre.

. However, the EAG was

uncertain to what extent the care pathway and treating clinicians would vary between hospital settings in included studies as compared to the UK. Of the other studies, two studies¹³²¹ were described as being set in medical settings and one study¹⁷ was described as being based within a virtual centre. Two studies^{14 25} were described as using data from unspecified settings with the USA.

Many of the included studies reported multiple analyses for the diagnostic accuracy of assisted and unassisted readers according to different staff grades (in addition to other relevant subgroups, such as age group and fracture location). As it was not possible to determine which analyses were most relevant to NHS staff who would be expected to use the technology in clinical practice, the EAG instead sought to categorise available data according to the level of experience as described by the publications: less experienced staff; highly experienced staff, and mixed or unclear levels of experience. The EAG noted that these categorisations were based on highly limited information and there is a high risk of error. Further information about this is provided in Section 5.1. Very few studies included staff that appeared comparable to those who would typically work within urgent care settings in the NHS, such as emergency care doctors or specialist trauma nurses.

Only three of the included studies specified the version of the technology under evaluation: in these studies, it was stated that Bousson 2023 evaluated BoneView version 1.0.2. and TechCareAlert version 1.7 (no version reported for Rayvolve), Radiobotics (2021) evaluated RBFracture version *** and Yogendra [unpublished] evaluated RBFracture version **. Descriptions of the output of the evaluated technologies was typically poor across studies, and therefore the EAG did not feel confident in differentiating between studies on the basis of features mentioned or not mentioned in the publications. For example, two studies^{13 16} evaluating BoneView reported that the technology provided readers with an indication of confidence in the result, either as a note on the result and/or as an altered boundary box around the area of interest.

However, the EAG considered it plausible that other studies included in the assessment also evaluated versions of the technology that provided a rating of confidence with results, and therefore did not use reporting of this feature to draw a comparison across studies. Similarly, three studies mentioned that staff received training in the AI prior to the study (Canoni-Meynet

 $*{\mathbb Z}^n$. The state $*{\mathbb Z}^n$ is the state $*{\mathbb Z}^n$ is the state $*{\mathbb Z}^n$

2022, Bachmann 2024, Radiobotics 2021), with varying levels of training ranging from months (Canoni-Meynet 2022) to written instructions and five training cases only (Bachmann 2024). The EAG considered it plausible that all studies would have trained readers in using the technology prior to the study, and that training was simply not described for most studies. The EAG therefore did also not use training requirements as a factor for comparing findings.

Where the same readers read the same exams assisted and unassisted, the washout period between assisted and unassisted readings ranged between no washout to three months (two studies $16\,25$ had no washout, four studies^{11 14 17 21} had 1 month washout,

, one study²³ had 2 months washout, and one study²⁴ had 3-months washout). The EAG considered that a washout of 1-month or longer was sufficient to ensure that the reading clinicians did not recall their previous responses to an X-ray, or at least would do so in very few cases. The EAG considered that there was a risk of bias associated with no washout period, as readers may be guided by their previous responses using the alternative method. Where washout was not reported, the EAG considered it more likely that no washout period was used, though of course this was not clear.

One of the studies used an index test that was considered not to be representative of the likely use of the technology: in this study to detect wrist fractures, rather than readers using the technology to reach a decision on diagnosis, the standalone results from the AI results and results of the original radiology report were artificially combined: an observation was considered positive when it was detected by either the AI or reported on IRR, regardless of the other's group result. The EAG considered this study to be at a risk of bias.

The reference standard used in the included studies generally included a decision from a senior radiologist, though there was some variation in the information that readers had to make their diagnosis (e.g. clinical information and medical notes, and access to further imaging). Where the reference standard was based on limited access to information about the patient and injury (as would be available within routine clinical practice), the EAG considered there to be an increased risk of incorrect judgements. Where a reference standard is determined to be imperfect, this affects the reliability of all the study results. The reference standard used in three studies (Canoni-Meynet 2022, Bousson 2023 and $\overline{}$ and $\overline{}$ included the results of the AI technology, and in a further study it was unclear whether this was the case (Oppenheimer 2023). The inclusion of these studies was a deviation from the review protocol (as described in Section 1) and was also associated with the potential for bias in the results, as it created closer

alignment between the results of the AI-assisted assessment and the reference standard. The EAG considered that the evidence from these studies should be interpreted with caution.

On the basis of information about the study design used by the included studies, and as described in Section 1), the EAG identified studies that provided the best quality evidence available within the evidence base and therefore could be used to inform the economic analysis. These decisions were based upon the following *post hoc* criteria: having a reference standard that did not include the AI reports, inclusion of results for both AI assisted and unassisted readers, relatively large sample sizes and peer-reviewed publication. Based upon these key criteria, the EAG considered the pivotal studies for each technology, to be as follows:

- **BoneView**: Duron 2021 (for adults) and Nguyen 2022 (for children and young adults).
- **RBFracture**: Bachmann 2024 (adults and children).
- **Rayvolve**: Two studies evaluated Rayvolve (Fu 2024 and Bousson 2023). Although limited by a relatively small sample size, Fu 2024 avoided the limitations noted above and was therefore considered by the EAG to be the pivotal study for this technology.
- **TechCare Alert**: Two studies evaluated TechCare Alert (Suite 2020 and Bousson 2023), both of which were associated with limitations as described above. Suite 2020 was also not presented in a peer-reviewed publication. Evidence for this technology was therefore of poorer quality than the studies listed above.

The EAG emphasises that all of these studies are associated with their own quality limitations that may undermine the reliability of the findings. In particular, none of the studies named above used a prospective design and may not be representative of clinical practice. Unfortunately, the two studies that included a prospective design were limited in other ways (see section 4.31.1.1) and were considered to be less reliable than those selected. Specifically, in Oppenheimer (2023), it was unclear whether the reference standard included the results of the technology, and Dell-Aria (2024) was a relatively small study.

Participant selection was also a key consideration in the selection: studies where participants were selected to ensure sufficient numbers of fractures (i.e. case-control designs, where 50% of the sample were selected for the presence of a fracture) would not have a fracture prevalence rate representative of clinical practice (and may also be unlikely to have a representative fracture location mix). These studies were not used to determine fracture prevalence in

economic analysis, and PPV and NPV estimates were considered to be unreliable. The pivotal studies by Duron 2021, Nguyen 2022 and Bachmann 2024 used a case-control design, but due to methodological issues with the other studies for these technologies, these studies remained the most robust for estimating sensitivity and specificity (prevalence, PPV and NPV were not extracted or considered from these studies). One of the studies that evaluated TechCare Alert (Suite 2020) also used a case-control design, with the other being limited in other ways (see 4.3). The relevant study sample from the pivotal Rayvolve study (Fu 2024) used random sampling. However, it is unclear, but appears likely, that the original dataset from which the sample were selected was based on a case-control design.

Important subgroups in the review were different staff grade/type and specific fracture locations (hand/wrist, foot/ankle, hip, elbow fractures in children and Salter-Harris fractures). The majority of studies provided some relevant subgroup data, with four BoneView studies (Canoni-Meynet 2022, Meetschen 2024, Dell-Aria 2024, Guermazi 2022), three RBFracture studies (Radiobotics 2021 (also Bonde), Bachmann 2023, Yogendra) and the Rayvolve and TechCare studies (Fu 2024 and Suite 2020 respectively) all reporting some DTA data for different staff types or grades and five BoneView studies (Canoni-Meynet 2022, Duron 2021, Ngyuen 2022, Oppenheimer 2023, Guermazi 2022) and the head-to-head study (Bousson 2023) reporting some DTA data for different fracture locations. Oppenheimer (2023) and Bachmann (2024) each reported subgroup data in children and young people.

Table 3: Study design of included studies

Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging; MSK, musculoskeletal; NR, not reported; PET, positron emission tomography

$4.2.2.$ Populations and reported prevalence

Demographics about the study sample used in the included studies, including prevalence rates of any and subgroup fracture types, are shown in As noted in Section 4.2.1, the EAG considered that studies using a case-control design would not provide prevalence data that was representative of clinical practice. The data from these studies should therefore be considered to only represent the case mix in the included studies and was not used as an estimate of fracture prevalence in the economic analysis. The EAG noted that the most methodologically robust study for the estimation of prevalence was likely Cohen 2023, but this study focused only on wrist fractures. Other studies that were reasonably robust for estimating prevalence were Dell-Aria 2024 and Fu 2024 (albeit both limited due to relatively small sample sizes), and

). Amongst the

studies that used consecutive and random sampling, rates of subgroup fracture types were rarely reported. Where these were available, these varied between studies, suggesting that the study samples included different underlying populations. As diagnostic accuracy for detecting fractures on X-rays varies according to fracture location, variation in case mix across studies will likely influence the findings.

Table 4. Studies with more reliable prevalence data (i.e. studies with consecutive and random sampling) are highlighted in bold.

Studies typically only included adults, or the vast majority of the sample were adults (see

). There were five studies^{10 11 16 17 23} that included a mix of adults, children and young people, of which two studies^{16 17} reported subgroup data specifically in children and young people. Two studies were conducted only in children and young people (Nguyen 2022 and Yogendra [unpublished]).

No studies reported frailty measures for its participants. Two studies⁷¹⁸ reported that the mean age of the sample was > 70 years. One study²⁴ conducted with participants with a median age of 39 years (no range reported) who had all experienced a low velocity trauma, and one study reported that 83.0% of injuries were due to falls. The EAG considered that all of these indicators may be correlated with frailty, but nevertheless wouldn't provide a meaningful representation of outcomes in people with frailty.

The EAG sought additional information from studies about the health of participants, such as the number of participants with diseases that affect bone health (e.g. osteoporotic disease). No studies reported this information.

Eight studies^{9-11 13 14 17 24 25} reported that a minority of participants had multiple fractures; where rates were reported, these ranged from 3.3% to 26% of the study sample. None of the studies excluded suspected dislocations and effusions, although only one study²² stated that the study sample included these injuries. Three studies^{7 13 24} explicitly excluded 'obvious' fractures, such as open fractures, displaced, and multi-fragmented and those caused from polytrauma, while other studies neither included nor excluded these. Within the EVA, the EAG did not extract information of the full range of fracture types included in the study samples from which to consider the case mix in which the technologies were evaluated. As noted in Section 4.2.1, the EAG considered that studies using a case-control design would not provide prevalence data that was representative of clinical practice. The data from these studies should therefore be considered to only represent the case mix in the included studies and was not used as an estimate of fracture prevalence in the economic analysis. The EAG noted that the most methodologically robust study for the estimation of prevalence was likely Cohen 2023, but this study focused only on wrist fractures. Other studies that were reasonably robust for estimating prevalence were Dell-Aria 2024 and Fu 2024 (albeit both limited due to relatively small sample

 $sizes$, and

Amongst the studies that used consecutive and random sampling, rates of subgroup fracture types were rarely reported. Where these were available, these varied between studies, suggesting that the study samples included different underlying populations. As diagnostic

accuracy for detecting fractures on X-rays varies according to fracture location, variation in case mix across studies will likely influence the findings.

Abbreviations: F, female; M, male; NA, not applicable; NR, not reported; SD, standard deviation

Note: Studies that used consecutive or random sampling, and therefore offer more reliable prevalence rate data, are highlighted in bold. * this is the number of fractures identified across the exams, meaning that a participant with multiple fractures would be counted more than once.

4.2.3. Outcomes

The outcomes reported by, or calculable from, the included studies are shown in Table 5. Sensitivity, specificity, and contingency tables were reported or calculable for all studies, although some data were missing for specificity and contingency tables for subgroup analyses (staff grade and fracture types) in two studies^{11 16}. PPV and NPV were either not reported or were not extracted for case-control studies. Additional outcomes reported by a small number of studies were the prevalence of fractures, as assessed using the reference standard (see Section 4.2.21.1.1), and the reading time for radiographs. The vast majority of outcomes listed on the NICE scope were not reported in any of the included studies (see Section 9).

Diagnostic accuracy that was reported per patient (i.e. a binary decision about whether a patient had a fracture) was typically reported across studies and prioritised for inclusion in the review. If these data were not provided, available per-exam or per-fracture data were extracted and these instances are highlighted in the results. The decision to prioritise per-patient data was made primarily because the majority of studies report data in this way and because these data are most relevant to the economic analysis. The EAG noted that the per patient approach allows for the assessment of one injury only, while the per-fracture approach accounts for accuracy across multiple fractures in the same person, and thus means that there will be multiple reports for the same participant. The per-exam approach is similar to the per-patient approach and usually reports on one injury per patient but may plausibly detect more than one injury in the same location. As noted in Section 4.2.2, the samples of eight of the studies included people with multiple fractures, all of which reported per-patient data, which were extracted for the assessment. These data therefore do not fully capture the rates of fractures in the study samples and may overestimate the sensitivity of the technologies (since a true positive result may be acquired even if all fractures in the same person are not identified).

First author (Date)	True positive	True negative	False positive	False negative	Sensitivity	Specificity	PPV	NPV	Reading time
BoneView									
Bousson (2023)	Y	Υ	Υ	Υ	Y	Υ	Υ	Υ	${\sf N}$
Cohen (2023)	Y	Υ	Ý	Υ	Y	Υ	Υ	Y	${\sf N}$
Canoni-Meynet (2022)	Y	Υ	Y	Υ	Y	Υ	Υ	Υ	Υ
Dell-Aria (2024)	Y	Υ	Y	Y	Y	Υ	Y	Υ	${\sf N}$
Duron (2021)	Y	Υ	Ý	Y	Y	Υ	NA	NA	Υ
Guermazi (2022)	Y	Υ	Y	Υ	Y	Υ	NA	NA	Υ
Meetschen (2024)	Y	Y	Ý	Y	Y	Υ	NA	NA	Y
Nguyen (2022)*	Y	Υ	Ý	Y	Y	Υ	NA	NA	N
Oppenheimer (2023)	Y	Y	Υ	Υ	Y	Υ	Υ	Y	${\sf N}$
Rayvolve									
Bousson (2023)	Y	Υ	Υ	Υ	Y	Υ	Υ	Y	N
Fu 2024	Y	Υ	Y	Υ	Y	Υ	Y	Y	Υ
RBFracture									
Bachmann (2024)	Y	Y	Υ	Υ	Y	Y	NA	NA	N
Jørgensen (S9 Abstract) (2023)	Y	Υ	Υ	Υ	Y	Υ	NA	NA	N
Radiobotics 2021 / Bonde	Y	Υ	Y	Υ	Y	Υ	NA	NA	N
Ruitenbeek (2024)									
Yogendra (NA)*				\blacksquare					
TechCare Alert									
Bousson (2023)	Y	Υ	Υ	Υ	Y	Y	Y	Υ	${\sf N}$
Suite (2020)	Y	Υ	Y	Υ	Y	Υ	NA	NA	N

Table 5: Outcomes available from the included studies

Abbreviations: N, no; NA, not applicable; NPV, negative predictive value; positive predictive value; Y, yes

Notes: *studies conducted in children only.

4.3. Quality appraisal of studies

As this was an EVA, no formal quality assessment of the included studies was conducted. Quality considerations that were considered to represent a potential source of bias have been discussed throughout the previous sections.

An overview of the way quality considerations influenced the interpretation of diagnostic evidence and the selection of evidence to inform the economic analysis are shown in Table 6. Coloured ratings are provided for ease of reference, though the EAG emphasise that these ratings are relative to each other and none of the included evidence was considered to be robust for diagnostic outcomes.

First	Index test and	Good for sensitivity and specificity?	Good for prevalence, NPV and PPV?
author	comparators		
(date)			
Head-to-head study			
Bousson		BoneView/Rayvolve/Te AMBER . Limited by the reference standard including AI results	AMBER. Good due to consecutive sampling, but limited by
(2023)	chCare Alert (no		the reference standard including AI results
	unassisted		
	comparator)		
BoneView			
Canoni-	BoneView assisted vs	AMBER. Limited by the reference standard including AI results	AMBER. Good due to consecutive sampling, but limited by
Meynet	unassisted		the reference standard including AI results
(2022)			
Cohen		BoneView standalone + $AMBER$. Limited by having no comparator (assisted only)	GREEN. Good due to consecutive sampling, NPV and PPV
(2023)	reader (no		limited to assisted only, limited to wrist only
	comparator) vs		
	lunassisted		
Dell-Aria	BoneView assisted vs	AMBER. Limited by relatively small sample size and reference	AMBER. Good due to consecutive sampling, but limited by
(2024)	lunassisted	standard decision by a single radiologist	relatively small sample size and reference standard decision
			by a single radiologist

Table 6: Quality considerations for the interpretation of diagnostic accuracy of the technologies

Abbreviations: NPV, negative predictive value; PPV, positive predictive value

5. CLINICAL, SERVICE AND TECHNOLOGICAL EVIDENCE RESULTS

5.1. Results from the evidence base and evidence synthesis

5.1.1. Diagnostic accuracy

The diagnostic accuracy of the technologies as reported by the included studies and/or calculated by the EAG are shown in Table 7. Data were calculated where these were not reported in publications. In some cases, calculated data varied slightly from that reported in the publication, which the EAG assumed was due to rounding errors, alternative methods for handling missing data, or reporting errors. The EAG selected the most reliable data for inclusion in the report tables and the evidence synthesis, meaning that some data (in all cases, rates of TP, FP, TN, FN) differed from those reported in the publications. As noted in Section 4.2.3, diagnostic data were calculated per patient (i.e. one result per patient, meaning that the analysis did not account for multiple fractures in the same person), unless otherwise indicated.

Only three studies^{13 17 21} reported outcomes for readers based within emergency care settings, each evaluating a different technology: one study¹³ compared assisted and unassisted readings with BoneView as read by emergency physicians; one study²¹ reported assisted and unassisted readings with Rayvolve as read by emergency physicians; and one study¹⁷ reported assisted and unassisted readings with RBFracture as read by A&E trainees or trauma-care nurses. Most of the included studies reported multiple analyses according to the level of experience of clinicians reading the X-rays. As the protocol for this assessment included a comparison of diagnostic accuracy across staff reading experience, evidence reported for readers of varying levels of experience was extracted. The EAG noted that those with more seniority and expertise in reading X-rays, would not be expected to use the technology in clinical practice and that these data are presented for comparison purposes only. To aid interpretation of the findings across reader experience, the EAG grouped results according to the description of reader experience and seniority described in the publications. As all of the included studies were based outside of the UK, staff grades used in the publications had unclear relevance to target clinicians within NHS settings, which meant that some groupings were uncertain. Three staff groupings were created: readers described by studies as having less experience with reading Xrays, including staff specified as being based within emergency settings as well as those stated to have less experience in reading X-rays; senior and expert staff, intended to be consistent with a consultant radiologist and reporting radiographer grade; and a mixed and unclear grouping, where results were reported for groups of readers who varied widely in experience level and

studies where reader descriptions did not fit easily within the less experienced and senior groups. The EAG noted that, in some studies, staff described as radiologists were nevertheless described as having less experience in reading X-rays, leading the EAG to assume that the term 'radiologist' may have a broader range of experience than would be expected within the NHS. In these cases, the EAG classified these as less experienced staff, though considered these groupings to be particularly uncertain, since descriptions in the publications may have been misleading.

Inspection of the results suggested that the groupings of studies according to reader experience was not particularly successful: in general, readers with greater seniority and expertise at reading X-rays were associated with more accurate diagnosis unassisted, though this was not universal across groupings. As this lacked face validity, the EAG assumed that the groupings according to reader experience were incorrect in some instances and so should be interpreted with caution when pooled (see Section 5.2).

Evidence from across the comparative studies generally suggested a trend for the technologies to improve sensitivity for diagnosing fractures in a mix of fracture types and across all reader groupings, but to have little or no impact on specificity. This trend was also present in those studies^{13 17 21} specific to readers based within emergency care settings. The comparability of outcomes between studies in emergency care settings was uncertain due to variation in the sensitivity of unassisted emergency physicians considered in both the Duron (2021) and Fu (2024) studies (sensitivity was reported as 61.3% in Duron and 79.2% in Fu), suggesting that staff experience or approach to decision-making varied between the studies. Nevertheless, the technologies improved sensitivity by a similar amount, with little or no change in specificity. Assistance with RBFracture in Bachmann (2024) improved sensitivity for trauma care nurses also by a similar amount, also with some benefit to specificity. The benefit to sensivitity for A&E trainees with RBFracture in the same study was smaller, with minimal benefit to specificity. However, in this study, unassisted A&E trainees had higher accuracy for detecting fractures unassisted than trauma care nurses and were no worse than either of the emergency physicians in Duron (2021) and Fu (2024).

5.1.1.1. Evidence from selected pivotal studies

The selection of pivotal studies for informing the economic analysis is described previously in this report. Nevertheless, the EAG cautions again that these studies were selected for being the most robust estimates within their design compared to other studies identified in the evidence base, but nevertheless still have limitations and should be interpreted with caution.

For BoneView, in a mixed group of readers including radiologists and ED doctors, Duron 2021 reported sensitivity as 79.4% (SD 7.4) when assisted by the technology and 70.8% (SD 12.5) when unassisted. Specificity was 93.6% (SD 4.6) assisted and 89.5% (SD 6.5) unassisted. All participants in this study were adults. Similarly, using readers who were radiology residents with variable levels of experience, Nguyen 2022 reported a higher sensitivity with AI assistance (82.67%, 95% CI 75.65, 88.36) than without assistance (73.17%, 95% CI 65.33, 80.07) and a higher AI assisted specificity (90.33%, 95% CI 84.43, 94.55) than without AI assistance (89.58%, 95% CI 83.55, 93.97). Nguyen 2022 reported subgroup data for children and young adults and these data are presented in section 5.1.2 alongside data for children from other studies.

For RBFracture the pivotal study of sensitivity and specificity estimates was Bachmann 2024 (albeit with the caveats described above). In this study, when readers were a mixed group of emergency care staff with a moderate level of experience, sensitivity was reported as higher with AI assistance (0.80, 95% CI 0.78-0.82) than without (0.72, 95% CI 0.70-0.73). Likewise, AI assisted specificity was higher (0.85, 95% CI 0.84-0.87) than unassisted (0.81, 95% CI 0.80- 0.83). Subgroup data were also available for children (see section 5.1.2), and for more junior staff (Table 7).

Similarly, the pivotal Rayvolve study (Fu 2024), provided sensitivity and specificity data for a mixed group of readers (emergency physicians, non-MSK radiologists, and MSK radiologists) and reported a higher sensitivity with AI assistance (0.955, 95% CI 0.944, 0.964) than without assistance (0.865, 95% CI 0.848, 0.881). In this study, specificity was similar with and without AI assistance (0.831, 95% CI 0.817, 0.845 and 0.826, 95% CI 0.812, 0.840 respectively). Subgroup data were available for emergency physicians (Table 7). The TechCare Alert study (Suite 2020) provided data only for junior radiologists and data were sparse and without confidence intervals (Table 7).

The EAG noted that although these sensitivity and specificity estimates may appear to differ across technologies, due to clinical and methodological heterogeneity between studies, and the overall paucity of robust data, it remains difficult to comment on whether any AI technology performed better than another. Although the head-to-head study (Bousson 2023) provided sensitivity and specificity data across three of the included technologies, the EAG highlighted

that these data were likely limited to a greater extent than the pivotal studies by the inclusion of the AI results in the reference standard. This study also did not include readers likely to be involved in emergency assessments of x-rays in UK clinical practice.

The pivotal studies for sensitivity and specificity estimates did not report other DTA data, due to study design features previously described. The EAG emphasised the need for caution when interpreting all DTA results (all studies are likely to be very limited), and in particular any prevalence, PPV and NPV estimates provided in the studies. When looking at the PPV and NPV data, the most robust data were from Cohen 2023, but these estimates were only relevant to wrist fractures (Table 7).

5.1.1.2. PPV and NPV from other included studies

Other studies with potentially reasonable designs for estimating PPV and NPV were Dell-Aria (2024) for BoneView, Ruitenbeek (2024) for RB Fracture, and Fu (2024) for Rayvolve (noting that Ruitenbeek and Fu are limited by the use of retrospective study designs, and Dell-Aria 2024 by a relatively small sample size). Indeed, of these three studies, only Dell-Aria reported PPV and NPV data (Table 7). The EAG calculated PPV and NPV for the other two studies but highlighted the potential lack of generalisability to clinical practice. For Fu 2024, for a mixed group of readers, the EAG calculated PPV was slightly higher with Rayvolve than without (61.92 and 58.86 respectively), as was NPV (98.49 and 95.52 respectively). Similar results were found for the junior readers, i.e. the EAG calculated PPV was slightly higher with Rayvolve than without (64.75 and 60.63 respectively), as was NPV (97.97 and 93.44 respectively). For Ruitenbeek, for a mixed group of readers, the EAG calculated PPV was slightly higher with RBFracture than without (* and * respectively), as was NPV (* and * respectively). PPV and NPV were overall lower for the junior readers but were similarly higher with RBFracture than without (PPV *** and **** respectively; NPV *** and *** respectively).

Abbreviations: CI, confidence interval; FN, false negative; FP, false positive; MSK, musculoskeletal; NA, not applicable; NPV, negative predictive value; PPV, positive predictive value; prev, prevalence; TN, true negative; TP, true positive

Notes: * calculated based on a crude midpoint between the two readers. ^ data is exam-wise. # data is fracture-wise.

5.1.2. Subgroup results (paediatric participants)

Four studies reported diagnostic accuracy data in a sample of children and young people: two studies²⁰²⁵ were conducted only with children and young people, and are also included in the previous section, and two studies^{16 17} reported subgroup data for children and young people. These data were in a mixed fracture population only and were only available in mixed/unclear and senior/expert reader groupings. The data are summarised in Table 8.

One of the studies¹⁶ evaluating BoneView reported 100% sensitivity for both assisted and unassisted readers. In other studies,^{17 20 25} the use of assisted readings with BoneView and RBFracture improved sensitivity for detecting fractures in children and young people but made no difference to specificity. Sensitivity for assisted diagnosis in these studies was high but would nevertheless result in more than 10% of positive fractures being missed.

Table 8: Diagnostic accuracy data for children and young people

Abbreviations: NPV, negative predictive value; NR, not reported; PPV, positive predictive value

Notes. *estimated. Prevalence in paediatric population wasn't reported, but case-control specified 50% fracture rate in overall sample and stratified by age

5.1.3. Subgroup results (fracture type)

The EAG identified diagnostic evidence separately for hand/wrist fractures, foot/ankle fractures, hip/pelvis fractures and Salter-Harris II fractures. These data are shown in Table 9.

Data for hand/wrist fractures were available for BoneView, Rayvolve and Smarturgences (Table 9). For BoneView, the studies with the most robust sensitivity and specificity data were likely to be Duron 2021 and Nguyen 2022 (albeit limited by their retrospective designs). For hand fractures only, and a mixed group of readers, Duron 2021 reported sensitivity to be higher with BoneView assistance than without (80.2%, SD 11.4 and 59.6%, SD 20.5 respectively). Specificity was also higher with BoneView assistance than without (91.0%, SD 6.4 and 84.7%, SD 11.0 respectively). Similarly, in Nguyen 2022, for a mixed group of readers interpreting hand/wrist X-rays, sensitivity was higher with BoneView assistance than without (87.08 95% CI 69.79, 96.46 and 68.75 95% CI 49.31, 84.32 respectively) although specificity was similar with and without BoneView assistance (88.33 95% CI 71.34, 97.1 and 87.92 95% CI 85.44, 89.48 respectively). PPV and NPV data were not available for these studies but are provided by Cohen 2023 in Table 9. For Rayvolve and Smarturgences one the head-to-head study provided subgroup data for hand/wrist fractures. The EAG again highlight the need to interpret these results with caution; the study was a retrospective which included the results of the AI in the reference standard.

For foot/ankle fractures, data were also available for BoneView, Rayvolve and Smarturgences (Table 9). Again, for Rayvolve and Smarturgences only the limited head-to-head study provided these subgroup data. For BoneView, the studies with the most robust sensitivity and specificity data were again likely to be Duron 2021 and Nguyen 2022 (albeit limited by their retrospective designs). For foot fractures only, and a mixed group of readers, Duron 2021 reported sensitivity to be higher with BoneView assistance than without (86.9%, SD 8.3 and 71.8% SD 13.6 respectively). Specificity was also higher with BoneView assistance than without (92.9% SD 5.8 and 88.0% SD 9.9 respectively). Similarly, in Nguyen 2022, for a mixed group of readers interpreting foot/ankle X-rays, sensitivity was higher with BoneView assistance than without (70.83 95% CI 51.47, 85.89 and 70.83 95% CI 51.47, 85.89 respectively). Specificity with BoneView assistance was 86.25 95% CI 68.77, 96.02 and without assistance was 85.83 95% CI 68.26, 95.79.

Although hip fracture data were available for BoneView and RBFracture (Table 9), the EAG noted that none of the pivotal studies reported these data. For BoneView, only Oppenheimer 2023 provided subgroup data for hip fractures, and despite being a prospective study, was limited by the inclusion of the AI results in the reference standard. Hip fracture data for RBFracture was either methodologically limited and unpublished (Bonde and Radiobotics 2021) or limited data from a published abstract (Jørgensen 2024, Table 9).

Only one study (Nguyen 2022; BoneView) provided data for Salter-Harris II fractures in children. As previously noted, although this study may provide reasonable sensitivity and specificity estimates, there is uncertainty surrounding this due to the retrospective study design. BoneView assisted sensitivity, for a mixed group of readers, was given as 92.26, 95% CI 71.29, 99.4 and unassisted as 80.95, 95% CI 57.41, 94.78. Specificity was not reported (Table 9).

Table 9: Diagnostic accuracy data for different fracture locations

Author (date).	Prevalence (reference standard)	Test	Less experienced readers assisted	Less experienced readers unassisted	Mixed or unclear reader assisted	Mixed or unclear reader unassisted	Senior and expert readers assisted	Senior and experts unassisted
Hand/wrist								
Bousson (2023)	97/314 (30.9%)	BoneView			Radiology residents (4 years of residency). Sensitivity 91.5 $(84.9 - 95.6);$ specificity 92.1 $(89.2 - 95.8)$ TP 89 FP 17 TN 200 FN ₈			
Canoni-Meynet $(2022)^{A}$	38/NR	BoneView	\overline{a}	÷	Radiologists assisted sensitivity: Hand 89.5% (33.9/38)	Radiologists unassisted sensitivity: Hand 68.4% (25.9/38)	\mathcal{L}	\cdot
Cohen (2023).	247/637 $(38.8\%);$	BoneView			l,		Artificial combination of $AI + initial$ radiology report. Sensitivity 88%(84-92); specificity 92%(89-95); PPV 88% (84- 92); NPV 93% $(90 - 95)$ TP 218 FP 29	Initial radiology report. Sensitivity 76 (70, 81); specificity 96 (94, 98); PPV 93 (90, 97); NPV87 (83, 90) TP 189 FP 14 TN 376 FN 58

Notes: ^ fracture-wise data

5.1.4. X-ray reading time

X-ray reading time with and without AI assistance was available for three technologies: BoneView (4 studies^{10 11 13 14}), RBFracture (2 studies^{17 20}, though only 1 study²⁰

) and Rayvolve (1 study²¹). The data for all fracture types (i.e. not for specific fracture locations) is shown in Table 10. Consistent with the diagnostic accuracy data, the EAG reported these data separately according to the perceived level of experience of readers, as described in the publications. There were no noticeable differences in reading time across the staff groupings, which was surprising given that reading time would be expected to be shorter for more senior staff.

Studies reported that BoneView and Rayvolve were both associated with a reduction in x-ray reading time across all staff groups: a reduction of 7 seconds per X-ray between means with Rayvolve, while reductions between means ranged from 2.6 to 13 seconds per X-ray with BoneView. One study reported that RBFracture

 $.$ However,

there were large standard deviations around reading time in all studies, which the EAG assumed may be due in part to the reading time varying widely according to the type and complexity of the fracture/injury. The EAG was also concerned about the reliability of how reading time would be measured in studies, and potential differences in the way this was defined and recorded between studies. This meant that the EAG had serious concerns about the reliability of the data and how to interpret differences between studies.

The EAG considered that reduced reading time for X-rays may have benefits for service resource, though were uncertain to what extent a difference of seconds per X-ray would mean to a service. However, the EAG also considered it plausible that increased reading times may be acceptable (and preferable) where the additional time translated to increased accuracy. Overall, based on the evidence available, the EAG tentatively concluded that BoneView may be associated with faster reading X-ray reading time, and that these findings should be considered alongside the results for its diagnostic accuracy.

	Less experienced staff		Mixed or unclear staff		Senior		
	With Al mean seconds per x-ray (SD)	Without Al mean seconds per x-ray (SD)	With AI mean seconds per x-ray (SD)	Without AI mean seconds per x-ray (SD)	With AI mean seconds per x-ray (SD)	Without AI mean seconds per x-ray (SD)	
BoneView (Gleamer)	52.8 (17.7) [Duron] 27(18); range 6, 114 [Canoni- Meynet] 44 (43) [Guermazi]	61.5(24.8) [Duron] 39(34); range 4, 313 [Canoni- Meynet] 57 (54) [Guermazi]	57.0 (49.4) [Duron] 49.2 (28.5) [Guermazi] 29.6 (19.8) [Meetschen]	67.0 (59.3) [Duron] 55.5 (32.6) [Guermazi] 32.2(20.8) [Meetschen]	40 (24); range 7, 163 [Canoni- Meynet]	50 (28); range 10, 180 [Canoni- Meynet]	
RBFracture (Radiobotics)			[Yogendra] 46.4 (NR) [Bachmann]	[Yogendra]	[Yogendra]	[Yogendra]	
Rayvolve (AZMed)	18 (NR) [Fu]	25 (NR) [Fu]	19 (NR) [Fu]	26.1 (NR) [Fu]	\blacksquare	$\qquad \qquad$	

Table 10: Reading time for assisted and unassisted X-rays (all fracture types)

Abbreviations: NR, not reported; SD, standard deviation

5.2. Evidence synthesis

The EAG investigated whether it was possible to meta-analyse data from the included studies, for example to identify a pooled estimate of sensitivity and specificity for a particular technology. Having identified significant variation in the diagnostic accuracy results according to reader experience, an assessment of the feasibility of meta-analysis was conducted with study results grouped according to the level of experience of readers outlined in Section5.1, as well as by fracture and technology type. A threshold of six studies within each grouping was considered sufficient for meta-analysis. The assessment identified that there were sufficient studies for meta-analysis in three categories:

(1) accuracy of unassisted emergency department and less experienced clinicians in reading xrays of any fracture type

(2) accuracy of unassisted mixed and unclear groups of clinicians in reading x-rays of any fracture type, and

(3) accuracy of BoneView when assisting a mixed or unclear group of clinicians reading X-rays of any fracture type.

On further investigation, however, there was unexplained heterogeneity in the results of the studies within each analysis, and meta-analysis was therefore not considered to be feasible. Specifically, plots of accuracy data varied significantly and there was a clear positive correlation between logit sensitivity and specificity, which suggested that at least one meaningful covariate was not included in the analysis²⁹. Within the EVA, it was not feasible to investigate further the potential reasons for heterogeneity in the data, which might have included a meta-regression to investigate factors that influence the accuracy of assisted and unassisted diagnosis.

The EAG took two further steps to synthesise the evidence base: (1) data from the included studies within each grouping was summarised using median and ranges, to give a concise insight into the variability of results across studies and (2) conducted a narrative synthesis to identify patterns in the data that could be used to inform an understanding about the potential value of the technology for assisting in the diagnosis of fractures. Synthesised data from the included studies is split by fracture type (general/all fracture types and specific fracture locations). The EAG advises that the synthesised results provide the median and range of sensitivity and specificity values reported in the studies and do not include any variance (e.g. 95% confidence intervals) around the data reported in the studies. This approach was used for simplicity and, due to limitations in the evidence base as a whole, including unexplained heterogeneity across studies, the results are presented to provide an insight into potential patterns across the dataset, rather than to identify precise diagnostic accuracy data for the technologies.

5.2.1. Diagnostic accuracy of the technologies across studies

Median sensitivity and specificity for each of the technologies as reported across study groupings are presented in this section. For ease of interpretation, the results are also presented as the median proportion of missed fractures and false positives. Section 5.2.1.1 includes the full study population included in the studies, representing multiple fracture types within the case mix of each study, as well as results for specific types of fracture subgroups (hand/wrist, foot/ankle, hip, and non-obvious fractures). Section 5.2.1.2 includes results specific to children and young people.

5.2.1.1. Mixed and subgroup fractures

Results for unassisted readers are shown in Table 11. The EAG noted that the rate of missed fractures for clinicians reading X-rays without AI assistance was high across studies, even for the senor and expert reader grouping (which was intended to be consistent with consultant-level radiologists and reporting radiographers). Across studies, the proportion of fractures missed ranged from 20 – 30% and was consistent across reader experience, though more experienced readers gave very few false positive decisions. The EAG consulted with two radiographers (authors NG and RM) to enquire whether the accuracy of unassisted diagnosis reported in the papers would be consistent with their expectations in clinical practice. They advised that the rate of missed fractures reported for more experienced staff in the included studies was higher than they expected; they expected that consultant radiologists and radiographers would be expected to miss very few fractures using X-rays (10% or less), even where readers were unable to consult medical notes and the results of other imaging modalities, as was typical in the studies. This would also be consistent with guidelines from The Royal College of Radiologists³⁰. The EAG sought robust data for the accuracy of X-ray for identifying fractures as used by readers of varying experience but was unable to identify this during the assessment. The EAG considered this to be a significant uncertainty in the evidence base, since uncertainty surrounding the generalisability of the data from the unassisted arms of the studies would also affect the way in which the results for the technology reported in the studies should be interpreted.

Sensitivity and specificity each varied significantly across studies though, in general, unassisted readers had higher specificity when identifying fractures than sensitivity. This resulted in a high median rate of missed fractures in all fracture analyses, though the rate of false positives was also over 10% in most studies in all reader groupings except senior and expert readers.

The accuracy of unassisted readers for detecting hip fractures was high. Sensitivity for detecting hand/wrist and foot/ankle fractures was lower than the mixed fracture analyses, and there was variability in specificity for detecting hand/wrist fractures across studies. As might be anticipated, there was greater variability in accuracy across studies reporting findings for groups of readers with mixed levels of experience, which likely represents the variable case mix in readers between studies. There was poorer sensitivity for identifying non-obvious fractures across all reader groupings.

Abbreviations: NA, not applicable; sens, sensitivity; spec, specificity

Note: data are the median and range of sensitivity and specificity values reported in studies or calculated by the EAG within each grouping. No variance data around the data are provided, however the specific values should be considered to be uncertain.

The results for BoneView as evaluated across studies are shown in Table 12. BoneView showed high sensitivity and specificity, irrespective of the reader group. Nevertheless, median numbers of missed fractures (all fracture analyses) exceeded 15% for all readers except the senior and expert reader group. As with unassisted results, there was some variability in sensitivity and specificity values reported across studies, particularly in analyses with mixed and unclear readings. In general, BoneView had improved specificity relative to sensitivity, with fewer false positives than missed fractures.

Sensitivity for non-obvious fractures was improved compared to the results for unassisted, although the rate of missed fractures and false positives was still high (43.8% and 21.1%) respectively, suggesting that services may still wish to use precautionary policies to avoid the risk of missed fractures. There was an improvement in sensitivity and specificity for detecting hand/wrist and foot/ankle fractures relative to unassisted. There was very little evidence for the accuracy of BoneView for identifying hip fractures, which reported high accuracy (both sensitivity and specificity), though not conclusively different from some of the unassisted evidence.

Abbreviations: NA, not applicable; sens, sensitivity; spec, specificity

Results for RBFracture as reported across studies are shown in Table 13. The sensitivity of RBFracture was broadly comparable to that of BoneView, although there was a trend for specificity to be worse, with similar rates of false positives across reader groupings as were reported for unassisted readers. This may reflect a prioritisation of the technology threshold towards sensitivity; i.e. prioritising the avoidance of missed fractures over avoiding false positives. However, rates of missed fractures were still generally high. There were fewer studies that evaluated RBFracture, and there was substantial variability in outcomes between studies. This creates more uncertainty in the findings. Notably, one study in senior readers had poor sensitivity compared to other reader groups; although this study was conducted in a paediatric population, which may have influenced the findings (see Section 5.2.1.2).

Table 13: Diagnostic accuracy of RBFracture across studies

Abbreviations: NA, not applicable; sens, sensitivity; spec, specificity

Results for Rayvolve are shown in Table 14. Two studies evaluated Rayvolve, both of which reported high sensitivity but poor specificity, particularly for hand/wrist and foot/ankle fractures. The EAG considered this was a feature of the technology algorithm, to prioritise missed fractures over false positives. Accordingly, specificity was comparable with unassisted diagnosis, while sensitivity was generally improved.

Group (n studies)	Median sens	Median spec	Median % missed	Median % over	
	(range)	(range)	#s (range)	diagnosis (range)	
Rayvolve all staff all	0.94(0.93, 0.96)	0.83(0.70, 0.85)	6.1% (4.4, 7.4)	16.9% (14.7, 29.6)	
fractures $(2)^{21}$ ²³					
Rayvolve junior all	0.94 (NA)	0.85 (NA)	6.1% (NA)	14.7% (NA)	
fractures (1) ²¹					
Rayvolve mixed all	0.94(0.93, 0.96)	0.77(0.70, 0.83)	5.9% (4.4, 7.4)	23.3% (16.9, 29.6)	
fractures (2) ^{21 23}					
Rayvolve mixed	0.98 (NA)	0.75 (NA)	2.1% (NA)	25.4%	
hand $(1)^{23}$					
Rayvolve mixed foot	0.91(0.91, 0.92)	0.67(0.63, 0.72)	8.0% (7.1, 8.9)	32.8% (27.9, 37.7)	
$(1)^{23}$					

Table 14: Diagnostic accuracy of Rayvolve across studies

Abbreviations: NA, not applicable; sens, sensitivity; spec, specificity

Results for TechCare Alert are shown in Table 15. Two studies evaluated TechCare Alert, with no crossover in the reader groupings, meaning that data was only available separately or in a group reporting results for any reader grouping. Both studies reported high sensitivity and specificity for TechCare Alert, with no rates of missed fractures and false positives. Results were improved compared to unassisted diagnosis. Results were similarly high for hand/wrist and foot/ankle fractures.

Group (n studies)	Median sens	Median spec	Median % missed	Median % over	
	(range)	(range)	#s (range)	diagnosis (range)	
TechCare Alert all	0.93(0.90, 0.95)	0.98(0.93, 0.98)	7.1% (5.1, 9.8)	1.9% $(1.9, 7.5)$	
staff all fractures					
$(2)^{22\,23*}$					
TechCare Alert	0.95 (NA)	0.98 (NA)	5.1% (NA)	1.9% (NA)	
junior all fractures					
$(1)^{22}$					
TechCare Alert	0.90 (NA)	0.93 (NA)	5.1% (NA)	1.9% (NA)	
mixed all fractures					
$(1)^{23}$					
TechCare Alert	0.93 (NA)	0.98 (NA)	7.1%	1.9%	
senior all fractures					
$(1)^{22}$					
TechCare Alert	0.94 (NA)	0.92 (NA)	6.2% (NA)	8.3% (NA)	
mixed hand $(1)^{23}$					
TechCare Alert	0.88(0.85, 0.90)	0.91(0.90, 0.92)	11.9% (9.5, 14.3)	8.6% (7.9, 9.2)	
mixed foot $(1)^{23}$					

Table 15: Diagnostic accuracy of TechCare Alert across studies

*2 studies and 3 data points as 1 study reported 2 staff grades

5.2.1.2. Subgroup results (paediatric participants)

Median results across studies reporting diagnostic accuracy data in children and young people only are shown in Table 16. No evidence was available in a less experienced reader group only. Amongst mixed or unclear experience readers, the assistance of BoneView or RBFracture improved median sensitivity for detecting fractures, though made no clear difference to specificity. In real terms, this reduced the number of fractures that were missed but did not change the number of false positives. One study that reported data for highly experienced staff reported poor sensitivity both with and without assistance with RBFracture, which lacked face validity. In this group of readers, the assistance of RBFracture improved sensitivity but this

came with a cost to specificity; i.e. there was a meaningful reduction in missed fractures but a large increase in false positive diagnoses.

5.3. Conclusions of the clinical, service and technological evidence

As an emerging technology, the evidence base for the clinical and service value of the technology for assisting with fracture diagnosis was expectedly limited. Nevertheless, within the context of an EVA, the EAG considered it notable that a total of 16 studies were identified and eligible for inclusion in the evidence review. Within the methods of the EVA, the EAG was appropriately broad in its inclusion criteria: including conference abstracts, non-peer reviewed reports, and manuscripts in preparation, all of which may not typically be considered within a NICE evaluation. The EAG also included a variety of study designs, including those with known limitations for determining reliable estimates for diagnostic accuracy. As the aims of an EVA include identifying an overview of the existing evidence base and key evidence gaps and research needs, the inclusion of this evidence was useful for these purposes. However, as stressed within the report, these studies are not robust for identifying reliable estimates of clinical and service outcomes and should be interpreted with caution.

The evidence base as a whole suggested that there is a need for further, high-quality research to evaluate the clinical and service outcomes associated with the technology (see Section 9). While several of the technologies had been evaluated in few studies available to date, there were nine and five included studies evaluating BoneView and RBFracture. For these technologies, the EAG considered that the time for a proof-of-concept of the technologies had passed, and that these technologies require evaluation within robust comparative study designs. These would include diagnostic randomised controlled trials and prospective, robustly sampled diagnostic studies, each set within the likely target settings and reader groups that would be expected to use the technology in clinical practice. To date, much of the evidence has focussed on the accuracy of the technology as a standalone tool (excluded from the evidence review as clinical standards would mean that this use would not be possible within the NHS) and as assistance to clinicians in radiology departments, including consultant-level staff, who would not be expected to require the use of the technology in clinical practice. In addition to the potential value of the technology for avoiding missed fractures, stakeholders to the assessment highlighted the potential value of the technology for service outcomes, such as time and resource savings, but this has not been a focus of any of the available studies to date. All this said, however, the EAG noted that the evaluation of the technology will be particularly complex in this field, as compared to evaluating diagnostic tools in other indications (see Section 9). In the same way as these complexities affected the ease of interpretation of the evidence base in this assessment, the EAG expected that some of these complexities would remain for any future NICE assessment, even with a more developed evidence base.

Given the limitations in the included studies, the EAG considered that the precise estimates of sensitivity and specificity reported in the studies were uncertain and may have limited generalisability to the outcomes that may be seen in clinical practice. However, across the evidence identified, there was a trend for the technologies to result in improvements in diagnostic sensitivity for identifying fractures relative to unassisted diagnosis, but minimal or no improvement in specificity for identifying where fractures were not present. This trend was seen across technologies and reader groups. Where accuracy of diagnosis unassisted by the technology was already high, such as in the identification of hip fractures and when used by senior readers with high accuracy, the additional value of the technology was evidently smaller. Generally speaking, the evidence showed that the use of the technology did not result in perfect sensitivity and specificity for any reader or any fracture type: while not unexpected, the implications of this were that the technology could not be relied upon to identify all fractures or

to never result in a false positive diagnosis. Within analyses of non-obvious fractures, where arguably the use of the technology could be greatest, the technology generally improved sensitivity but was still associated with a large number of false negatives that would require handling through additional service use (e.g. imaging, consultant review, precautionary tactics, patient recall). While studies mostly reported that use of the technology may reduce reading time for each X-ray by several seconds, advice from clinical experts was that this may not be preferable, as the technology should – using best practice – be an add-on step of the care pathway and thus result in overall increased time for diagnosis within services.

In conclusion, on the basis of the available evidence base, the EAG considered that there are early indications that the use of the technology to aid identification of fractures could have value for avoiding missed fractures. Further evidence is needed to evaluate whether this potential holds true for the specific ways in which the technology could be used within the NHS, including the target fracture types, readers, and the broader care pathway used within each of the target settings. There was some evidence that accuracy may vary across the technologies evaluated, however due to the lack of evidence for some technologies, and variation in study designs used to evaluate each technology, this was uncertain. There is also a need to determine the potential implications of the technology for broader service use outcomes, particularly to determine any potential trade-off between increased time to diagnosis with other potential time and resource savings. Further evidence is also needed to determine the clinical outcomes associated with any difference in diagnostic accuracy and service use.

6. ECONOMIC EVIDENCE SEARCHES AND SELECTION

6.1. Evidence search strategy and study selection

A single search was conducted to identify clinical, technological and economic evidence. Please see Section 4.1 for details of the evidence searches.

6.2. Included and excluded studies

A total of 1907 records were retrieved by the database searches plus 90 records identified by other sources. Of these, 654 records were excluded as duplicates, resulting in 1343 records to be screened by title and abstract. From this screening, 75 records were selected for full-text retrieval. In total, the review included 4 studies that informed health state costs and utilities: these are summarised in Table 17

A list of studies excluded along with the rationale for exclusion is provided in Appendix C. A PRISMA diagram of the search and screen process is provided in Appendix B.

Table 17: Key studies selected for the economic model

7. EVIDENCE SUBMITTED BY COMPANIES

Three companies (Gleamer, Milvue and Radiobotics) submitted a RFI response to inform this assessment, no RFI was received from AZmed or Qure.ai. As part of the RFI responses, each company provided details about evaluations of their technologies that may be relevant for consideration within this assessment. These studies were screened using the same methods described in the protocol for the assessment, meaning that they were included where they met the inclusion criteria for the evidence reviews. This included two unpublished manuscripts, currently in preparation, submitted by Radiobotics. Studies that were excluded during screening are listed in Appendix C alongside the reasons for exclusion.

A number of studies described by companies in their RFI responses were identified by the EAG as plausibly relevant but there was insufficient information to determine their eligibility for the assessment. This included studies where:

- It was unclear whether the technology was evaluated as a standalone diagnostic tool or whether the technology was used in conjunction with clinician judgement.
- An incomplete citation was provided by the company, and it was not possible to identify the publication source.
- Results were not provided for any of the outcomes in the NICE scope or data were presented in an unusable format.

In all such cases, the EAG submitted a request for clarification from the companies who submitted RFIs (Gleamer, Milvue, and Radiobotics).

Similar uncertainties were identified for several studies identified by the EAG in its evidence review, in addition to uncertainties regarding the name of the technology evaluated. Requests for clarification were submitted to companies where they were listed as a study sponsor and/or where staff from the company were listed as a study sponsor (Gleamer, Milvue, AZmed, and Radiobotics).

Where no clarification response was received by the companies, any studies that did not clearly meet the review eligibility criteria, as outlined above, were excluded.

8. ECONOMIC EVALUATION

8.1. Quality appraisal of selected studies

Consistent with the methods for an EVA, no formal quality appraisal of included studies was undertaken.

8.2. Relevant economic models

Four papers relevant to the topic area were identified and used as a basis for this assessment, specifically providing information on the payoffs (cost and QALYs accrued) from the diagnostic outcomes of true and false positive and negative. An overview of these publications is provided in Table 17.

- Rua (2020)³¹ conducted an assessment for the wrist, evaluating the cost-effectiveness of immediate magnetic resonance imaging (MRI) in managing patients with suspected scaphoid fractures. The clinical outcomes were sourced from the SMaRT trial, which recruited participants with negative initial radiograph findings at the emergency department of a central hospital in London.
- Nwankwo (2022)³² calculated the incremental cost-effectiveness of a removable brace vs plaster cast in the management of adult patients with ankle fractures. The outcomes were derived from the Ankle Injury Rehabilitation (AIR) trial, a UK-based pragmatic multicentre randomized controlled trial (RCT). Eligible patients presented to the hospital with an ankle fracture, whether treated operatively or non-operatively, for which the clinician deemed a cast a reasonable management option.
- Low (2021)³³ analysed the utilities associated with hip fractures, comparing the costs and QALYs of different imaging strategies for diagnosing occult hip fractures. The study compared magnetic resonance imaging (MRI) with dual-energy computed tomography (DECT), single-energy computed tomography (SECT) supplemented with DECT, and SECT alone.
- Judge (2016)³⁴ evaluated the cost-effectiveness of three models of secondary fracture prevention for all patients with hip fractures admitted to NHS hospitals.

Further details on how the data were used are described from Sections 8.3.4 to 8.3.6.

8.3. Economic model

The EAG developed a *de novo* model to explore the potential cost-effectiveness of AI-assisted diagnosis of fracture compared with unassisted diagnosis of fracture in an urgent care setting from the perspective of the NHS and Personal Social Services (PSS).

Given the heterogeneous nature of the subsequent costs and consequences of different fracture locations, the EAG divided the analysis into three separate decision problems, focussing on diagnosis and treatment of (1) wrist and hand fractures, (2) ankle and foot, and (3) hip. These three fracture sites were chosen as being both where the EAG considered there to be opportunity for greatest benefit from AI-assisted diagnosis and where the costs and consequences of the fractures differed substantially, warranting separate modelling. The outputs of these were then weighted based on the case mix of a typical urgent care setting to estimate the overall change in costs and QALYs accrued within that setting attributable to AIassisted diagnosis. Scenario analyses explored additional adjustment for use of AI in diagnosing fractures other than the three types explicitly modelled.

The model described below represents a very rapid overview of the likely costs and consequences associated with use of several commercial AI algorithms to assist in the diagnosis of fracture, and unassisted diagnosis, in an urgent care setting. The purpose of this analysis approach was to explore whether there was a *prima facie* plausible case for any of the technologies to represent value for money for the NHS / taxpayer within the context of a NICE EVA. The results should therefore not be used as a definitive estimate of the costs, effects and cost-effectiveness of the interventions: a more thorough analysis may lead to different conclusions.

8.3.1. Model structure

The model structure (Figure 1) comprised a decision tree incorporating the prevalence, sensitivity and specificity and cost per diagnosis of a strategy (i.e. AI-assisted or unassisted diagnosis). The model structure allowed up to two reviews of a radiograph, although the model could be simplified to just a single review (e.g. where input data either represent just a single view, or where accuracy data are presented for a double-reading process alone, without disaggregation by reader). Allowing for two reviews generated eight terminal nodes, two each for four possible states of the world: true positive, true negative, false positive and false negative. Payoffs in terms of costs and QALYs were attached to these, drawing on previous relevant studies in the literature. The prevalence in this case was defined as the proportion of

patients arriving in the urgent care setting with a suspected fracture who have a fracture. Payoffs attached to each terminal node are described in Sections 8.3.4 to 8.3.6. Details on how the three models were combined to estimate the overall impact on a 'typical' urgent care setting are in Section 8.3.7.

Square = decision node; Circle = chance node; Triangle = terminal node. $D+$ = prevalence (i.e. probability of a suspected fracture being a true fracture); $D = 1 - D +$; T1+ = conditional probability of a positive result from first review of X-ray (in branch shown this is sensitivity); T2+ = conditional probability of a positive result from second review of X-ray. Costs and QALYs are assigned to terminal nodes. Image drawn with SilverDecisions (silverdecisions.pl)

8.3.2. Model assumptions: EAG base case and scenario analyses

The EAG base case assumed that patients present in an emergency department with a suspected fracture, which can be one of three or four types: ankle or foot, wrist or hand, hip or 'other'. The base case assumed that AI-assisted diagnosis was limited to ankle/foot, wrist/hand and hip fractures alone and so only considered these fracture types. A scenario analysis (scenario 8) assumed that the software was used to read radiographs for all suspected fractures (including 'other').

As the cost of the emergency department attendance and X-ray (including the grade of staff reading the x-ray) was common to all comparators in this analysis, these costs were excluded. The difference in cost between different technologies was therefore limited to the cost per scan.

This also meant that the cost of reading the scans were directly transferrable to other urgent care settings (i.e. UTC and MIU). Sensitivity and specificity of the diagnosis was assumed to depend on the grade of staff reading the scan, rather than the setting where it took place.

The decision problem addressed in the EAG base case was to explore the cost-effectiveness of AI-assisted diagnosis using four technologies (BoneView, Rayvolve, RBfracture and TechCare Alert) and unassisted diagnosis of fracture in the urgent care setting from the perspective of the NHS & PSS.

8.3.3. Sensitivity and specificity of diagnosis

Two of the studies identified in the literature review were selected as sources for prevalence and sensitivity and specificity of each diagnostic strategy. Whilst all studies had strengths and limitations, and a number of potentially relevant studies for the decision model were identified in Section 4.2.1, Bousson et al. (2023)²³ provided directly comparative data between BoneView, Rayvolve and TechCare Alert. Furthermore, data were disaggregated by foot, ankle and hand (but not hip). For the base case, the EAG estimated a mean sensitivity and specificity for foot and ankle, assumed hand applied equally to wrist, and assumed the sensitivity and specificity of hip fracture diagnosis was equal to that for 'all fractures'. Bachmann et al. (2024) compared RBFracture assisted diagnosis to unassisted diagnosis in a wide range of fracture types, reporting results by 'mixed' staff types, ED trainees and trauma care nurses. This was used as the source study for RBFracture and unassisted diagnosis, with diagnosis by "A&E trainees" considered the closest match to that in Bousson ("radiology residents" with four years' experience). Due to concerns about quality limitations in the studies, the EAG did not seek to adjust estimates for differences in the characteristics of these studies, and a full network metaanalysis of source studies is recommended in future work. Instead, the EAG explored optimistic and pessimistic scenarios in the analysis (see Section 8.3.10). As data were not disaggregated by fracture type, the base case assumed the same sensitivity and specificity for all fracture types for RBFracture and unassisted diagnosis.

Source studies estimating the sensitivity and specificity of diagnosis assumed a single read of a scan. To ensure as fair a comparison between technologies, the EAG base case assumed only a single read. A scenario analysis including a second read of all scans was included as the EAG considered that this was a more realistic approach for clinical practice. Base case input data (including parametric distributions for the probabilistic analysis) are summarised in Table 18.

Notes: Table reports means and probability distribution and parameters used in analysis. Payoffs for each fracture type are described in the following sections (8.3.4 to 8.3.6).

8.3.4. Foot and Ankle

Based on the WHO Global Burden of Disease 2019 report,³⁵⁻³⁷ Chen et al.³⁸ estimated that in the UK in 2019, the age standardised incidence of foot fracture was 202.64 per 100,000 (95% uncertainty interval (UI) 142.23 to 278.04). Globally, foot fracture incidence exhibits a bimodal distribution by age, with peaks amongst the very elderly (80+) in both men and women and at around age 20-24 in males and 10-14 in females. Overall incidence is higher in men than in women, although is similar amongst the very elderly.

Two previous economic studies were identified as potential sources for data for this analysis. Nwankwo et al. (2023)³² reported the results of a within-trial cost utility analysis comparing removable brace with cast in patients with ankle fractures aged 18+ over 12 months, whilst Baji et al. (2023)³⁹ reported the results of a within-trial economic analysis over 12 weeks. Health state utilities measured in Nwankwo et al. at 6 time points showed continuing improvement in both arms, suggesting healing continued over this time horizon. In the absence of data to the contrary, the foot and ankle fracture model assumed a time horizon of 12 months (i.e. implicitly assuming that there will be no difference in cost and outcomes between patients with and without fractures after this point). The Baji 2023 study was not considered further as a source for extracting payoffs due to its short time horizon.

In this analysis, patients were assumed to present to urgent care with a suspected fracture following a trauma. The two states of the world were for the ankle or foot to be broken, or for it to have sustained soft tissue injury alone. In the case of a soft tissue injury, the patient was assumed to remain in pain for a short while (e.g. 2 weeks), before returning to normal health.

The time horizon of the source study was one year. Payoffs in terms of costs and QALYs for the four possible outcomes are described below.

True positives

Nwankwo (2023)³² reported health state utilities for patients experiencing ankle fractures over one year using the EQ-5D-5L instrument, yielding 0.723 QALYs for patients with brace and 0.720 for those treated with cast. The EAG assumed that 50% of patients would be treated with a brace and 50% with a cast. As allocation amongst the trial was almost exactly 50/50, the weighted average QALYs accrued was 0.722 (SE 0.06), which was assumed to be the QALYs associated with a true positive diagnosis of a foot or ankle fracture (Table 19).

	Brace	Cast	Total
n	335	334	669
QALYs mean	0.723	0.72	0.722
QALYs SD	0.153	0.149	0.151
SE	0.008	0.008	0.006

Table 19 Calculation of QALYs associated with true positive detection of ankle / foot fracture

Source: Nwankwo et al. 2023

NHS and personal social services costs over 12 months were estimated at £995.54 (SE £130.68) in the brace arm and £717.47 (SE £47.70) in the cast arm (2019/20 prices). This included ED visits, in-patient days, medication, community health services, outpatient visits, aids and adaptations to the home and personal social services (as described in Nwankwo 2023 supplementary material³²). Following confirmation with the author, the ED visits measured in the study did not include the index attendance (i.e. initial presentation at ED with a suspected fracture). As per the assumptions for calculation of QALYs, the EAG assumed a 50/50 split between the two approaches and adjusted the price year with the NHSCII pay and prices index yielding a mean cost of £1,837.23 (SE £71.03) in 2022/23 prices (Table 20).

Table 20 Calculation of costs associated with true positive detection of ankle / foot fracture

12 m NHS+PSS cost	Brace	Cast	Mean	2022/23 prices
N	335	334	669	
Mean	£995.54	£717.47	£856.71	
SD	£2,391.74	£871.77	£1,632.89	£1,837.23
SE	£130.67	£47.70	£63.13	£71.03

Source: Nwankwo et al. 2023

True Negatives

A patient who is correctly diagnosed as not having fractured their ankle or foot was assumed to incur the cost of the index emergency department consultation and then be discharged (the index consultation is excluded from the analysis as is common to all arms).

To estimate QALYs, patients were assumed to endure the health state equivalent to a fracture for two weeks (representing pain and soft tissue bruising from the injury causing them to seek assistance), before reverting to the 'healed' health state utility for the remainder of the year. This led to a mean QALYs accrued over 1 year of 0.796 (Table 21). Utilities and durations were entered in the model with QALYs calculated dynamically from sampled values of both. Due to

lack of data, correlation between utility at the timepoints was assumed zero (i.e. independent). This will overestimate the distribution of sampled values of QALYs (i.e. overestimate uncertainty in QALYs). The utility associated with ankle/foot fracture (0.225) was considered to lack face validity for a soft tissue injury. Therefore, scenario analysis explored alternative assumptions.

	Brace		Cast		Total		
N	335		334		669		
	mean	SD	mean	SD	mean	SD	SE
Utility 1 (SD)	0.212	0.310	0.238	0.311	0.225	0.310	0.012
Duration 1					2		
Utility 2 (SD)	0.812	0.192	0.825	0.171	0.818	0.182	0.007
Duration 2					50		
QALYs					0.796		

Table 21 Calculation of QALYs associated with true negative ankle / foot fracture

Source: adapted from Nwankwo et al. 2023

False Positives

A false positive was assumed to accrue the same cost as a true positive patient and to accrue the same QALYs as a true negative.

False Negatives

Patients with a fracture who were wrongly diagnosed as not having a fracture were assumed to re-present in the ED after two weeks, whereupon additional investigations would be conducted, and a correct diagnosis made. Clinical advice to the EAG was that a patient would either present to their GP or represent in the ED. A plausible timeframe was considered to be within a month. They therefore incur the same costs as true positives (£1837.23, Table 20), plus a cost for additional examinations (£149.04, see Section **Error! Reference source not found.**), yielding a total of £1,986.27. To calculate QALYs, the patient was assumed to remain in the base health state for two weeks before following the utility trajectory of a true positive patient, trimmed to 52 weeks (Table 22).
	Brace		Cast		Total		
N	335		334		669		
	Mean	SD	mean	SD	mean	SD	SE
Utility 0	0.212	0.310	0.238	0.311	0.225	0.310	0.012
Utility 1	0.212	0.310	0.238	0.311	0.225	0.310	0.012
Timepoint 1					$\overline{2}$		
Utility 2	0.534	0.258	0.497	0.272	0.516	0.265	0.010
Timepoint 2					8		
Utility 3	0.660	0.180	0.647	0.192	0.654	0.186	0.007
Timepoint 3					12		
Utility 4	0.73	0.177	0.702	0.198	0.716	0.187	0.007
Timepoint 4					18		
Utility 5	0.778	0.176	0.767	0.193	0.773	0.184	0.007
Timepoint 5					26		
Utility 6	0.809	0.192	0.821	0.171	0.815	0.182	0.007
Timepoint 6					52		
QALYs \sim \sim dental from Museulane \sim \sim 0000 \sim \sim					0.697		

Table 22: Calculation of QALYs associated with false negative ankle / foot fracture

Source: adapted from Nwankwo et al. 2023

Summary of key assumptions

- Ankle fractures would be healed within 12 months.
- TN incur the cost of an ED attendance
- TN accrue QALYs based on 2 week's baseline utility from Nwankwo et al. followed by the remainder of the year at the 'healed' utility from Nwankwo et al.
- FP incur the same cost as TP, same QALYs as TN (2 weeks of pain then back to normal)

8.3.5. Hand and Wrist

Six previous economic evaluations^{17 31 40-43} of interventions for hand and/or wrist fractures were identified, of which two were UK-based and therefore of most relevance to this study question (Rua et al. 2019⁴³ and Rua et al. 2020³¹). Both studies reported the results of the same randomised controlled trial of a second line diagnostic of immediate MRI vs no MRI in patients

with a suspected scaphoid fracture who had a negative X-ray (i.e. the sum of true and false negatives from the initial X-ray). The full cost-utility analysis (Rua et al. 2020) was used as the primary source for this analysis.

As Rua et al. 2020 compared immediate MRI with no MRI (control), the results were presented in an aggregate manner, without distinguishing between False Negatives and True Negatives. Consequently, the EAG drew on the control arm data to populate the costs and consequences of all four terminal nodes.

Utilities were measured at four timepoints to a time horizon of six months. Resource use comprised primary and secondary care contacts including fracture clinic appointments, subsequent ED visits, additional diagnostics, surgery, physiotherapy, splits and plaster casts.

The time horizon for the source study was six months. Payoffs in terms of costs and QALYs for the four possible outcomes are described below.

True Positives

The EAG assumed utilities for True Positive hand/wrist fractures were one standard deviation lower for three months, compared to those reported in Rua et al. 2020. This assumption was required as the aggregated results encompassed patients both with and without fractures (Table 23). Standard errors were assumed as per those reported in Rua et al. 2020.

Source: * Rua et al 2020; ** EAG calculation

Abbreviations: QALY, quality-adjusted life-year; SD, standard deviation, SE, standard error

Abbreviations: N, sample; SE, standard error

True negatives

The utilities for True Negatives were assumed to be equal to those reported in Rua et al. 2020, as 89.6% of patients in the control arm confirmed the absence of fractures. The EAG noted that this resulted in a moderate underestimate of QALYs accrued due inclusion of 10.4% of fractures (Table 25).

Table 25 Utilities for True Negative population

Abbreviations: QALY, quality-adjusted life-year; SD, standard deviation, SE, standard error

Similarly to the utilities, the costs derived from the publication are assumed to align with a True Negative population.

Table 26 Costs for the True negative population

Abbreviations: N, sample; SD, standard deviation; SE, standard error

False positives

As for true negatives, the utilities for false positives were assumed to be consistent with those reported in the publication, given 89.6% of patients in the control arm confirmed the absence of fractures. This may overestimate utility gains as it may be the case that treating false positives as positives may result in disutilities.

Table 27 Utilities for the False positive population

Health state	Utility (mean)	SD	SE
Baseline	0.786	0.158	0.020
month	0.747	0.238	0.030

Abbreviations: QALY, quality-adjusted life-year; SD, standard deviation, SE, standard error

The costs associated with True Negatives and False Positives differ, as the latter group is treated similarly to those with fractures until a subsequent diagnostic test confirms otherwise. Therefore, the base case resource utilisation for this population is assumed to be 10% higher than that of the publication.

Table 28 Costs for the False positive population

Abbreviations: N, sample size; SE, standard error

False Negatives

Regarding QoL, this population closely resembled that of true positives. However, it was assumed that patients in this group would be mistreated as negatives for the first two weeks following their presentation to urgent care, and therefore would not accrue QoL gains during this period. Furthermore, as observed in the true positive population, it was assumed that the utilities were lower by one standard deviation for up to three months compared to those reported in the publication. Finally, it was assumed that the QoL for patients after three and a half months of treatment aligned with the values reported in the publication.

Table 29 Utilities for the False negative population

Health state	Utility (mean)	SD	SE
Baseline	0.628	0.158	0.020
2 weeks	0.628	0.158	0.020
6 weeks	0.509	0.238	0.030
14 weeks	0.843	0.227	0.028
26 weeks	0.843	0.211	0.026
QALYs for 6 months	0.329		

Abbreviations: QALY, quality-adjusted life-year; SD, standard deviation, SE, standard error

Differences in resource use from the true positive population include an additional 5% of patients likely to undergo wrist surgery, as suggested by Rua (2020), and the inclusion of an extra visit to the emergency department.

Table 30 Costs for the False Negative population

Abbreviations: N, sample size; SE, standard error

Summary of key assumptions

- All health states:
	- \circ QoL after 3 months aligned with that of the publication as patients can be considered "cured"
	- \circ 6 months is a long enough time horizon to capture all QoL and costs differences
	- \circ The utilities and resource use from Rua et al. 2020 are representative of those of True negatives in the UK
- True positives
	- \circ Utilities for the first 3 months are equal to one standard deviation below those reported in Rua et al 2020.
	- o Resource use data
- False positives
	- \circ The utilities of Rua et al. 2020 are representative of this population
	- o Resource use associated to this health state is 10% higher than that of True negatives
- False negatives
	- \circ Patients return to urgent care two weeks after the initial presentation following which their fracture is correctly diagnosed
	- \circ Following from the above, the utility from Rua et al 2020 at baseline represent the utility for those 2 weeks, therefore not assuming disutilities in that period.

8.3.6. Hip

Six economic evaluations for hip fractures were identified. One study was UK based (Judge et al 2016 34) and provided the lifetime costs of hip surgeries for usual care (UC), fracture liaison nurse (FLN) care and orthogeriatrician (OG) care models for delivery of secondary fracture prevention after index hip fracture. Other studies were conducted across different geographies (EU/Singapore/America) of which Low et al 2021³³, a Singapore based decision model comparing different diagnostic strategies for occult hip fractures provided utilities for hip fracture by age group and different time periods following the fracture (i.e. immediate, during first year and after first year following fracture) was used, as the study design was aligned with the decision problem scope and included a detailed model inputs table (along with the associated uncertainty parameters).

The time horizon for the source study was lifetime. Payoffs in terms of costs and utilities for the four possible diagnostic outcomes are described below.

True positives

Low et al 2021 reported utilities for hip fracture for 65–74-year-old and also at different time points following the index hip fracture (immediately following fracture, during first year following index hip fracture and beyond first year). Table 31 shows the mean utilities and uncertainty distributions inserted into the model based on Low et al.

Note: * Assuming lifetime horizon until 83 years of age (female life expectancy in line with Low et al 2021)

As the Judge et al. study was UK-based, the EAG considered it to be the preferred source for resource use and costs. This study comprised a lifetime Markov model with 1-year cycles that simulated the natural history of hip fractures, including progression, major non-hip fractures, and discharge to home or a care facility. The study further provided the intervention, hospital,

primary care and care home costs by male and female cohorts and by different care models namely usual care, FLN and OG care.

Table 32 below provides the mean discounted costs which is an average across all models of care with the assumption that patients were equally distributed across those models of care (namely UC, FLN and OG). This approach was taken as the population concerned was over 60 years typically having fragility related fractures, where FLN and OG care models could also be useful in addition to usual care. Standard error was not available; therefore, it was calculated from 95% CIs (upper and lower limits) provided (i.e. SE = upper limit – lower limit/3.92).

Table 32. Mean discounted costs across different models (usual care, FLN and OG) of secondary prevention care following hip fracture (2022/23 prices)

	Mean	SE (calculated using 95% CI)
Total Male costs	£40,628	£749
Total female costs	£52,050	£603
Average costs	£57,471	£834

Abbreviations: UC, usual care; FLN, fracture liaison nurse; OG, orthogeriatrician; LCI, lower confidence interval, UCI, upper confidence interval

True negatives

A patient who was correctly diagnosed as not having fractured their hip was assumed to incur the cost of an emergency room consultation and then be discharged. They were assumed to be experiencing health state equivalent to a post-fracture immediately for two weeks (to account for the pain and short-term impact of injury), before reverting to the baseline health utility (0.79 as shown in table below). Utilities and durations were used in the model to calculate QALYs dynamically from sampled values of both. Due to lack of data, the utility values at different time points were assumed to be independent.

* Assuming lifetime horizon until 83 years of age (female life expectancy in line with Low et al 2021)

False positives

As per Low et al 2021, people with false positive results would be treated as having a hip fracture and would undergo surgery similar to true positives. Therefore, their costs would be the same as those of true positives. However, as they do not actually have the fracture, their utilities would be assumed to be the same as true negatives. The EAG noted that false positives were less likely to undergo surgery as the incorrect diagnosis was likely to be spotted before this point. The cost estimate for this analysis may therefore be an overestimate.

False negatives

Low et al. mentioned that people with false-negative results would be discharged only to return to ED within a month for hip surgery, following which they would have the same pathway as true positives.

In terms of costs, the same costs as true positives were incurred, plus costs for additional ED attendance and further imaging (CT was assumed), as given in Table 35.

Table 34. Utilities for False negative hip fractures

* Assuming lifetime horizon until 83 years of age (female life expectancy in line with Low et al 2021)

Table 35. Costs for false negative hip fractures

Summary of key assumptions

• Long term costs and consequences for hip fractures were assumed for lifetime horizon (one index surgery followed by a second surgery assumed) as per Low et al 2021.

- False negatives were assumed to incur the same costs as true positives with additional costs of an ED attendance and any additional investigations (1 CT assumed). Time for return after discharge was assumed to be 1 month or 4 weeks for false negatives based on Low et al 2021.
- True negatives incurred the cost of an ED attendance and accrue QALYs based on immediate post-fracture utility applied for initial 2 weeks, following which they were assumed to return to baseline utility for 65-74 years.
- False positives incurred the same cost as true positives as per Low et al 2021 and same QALYs as true negatives.

8.3.7. Overall impact of AI-assisted diagnosis in an urgent care setting

Clinical advice to the EAG was that over 2022-23, there were approximately 25.3 million ED attendances in England and that fractures typically account for 2-4% of all visits, equating to between 506,000 and 1,012,000 attendances. Clinical advice suggested that around 12.5% of all fractures are ankle, 7.5% wrist and 12.5% are hip. Data specifically including ankle and foot, and wrist and hand were not available. However, the EAG assumed that these proportions represented the base case distribution to estimate the overall impact of diagnosis in an urgent care setting (Table 36). Scenario analysis included the use of the technology for all fractures.

These figures were multiplied by the number of patients per year expected in a 'typical' ED with 350-400 attendances per day (total attendances, not just fracture). This equated to 136,875 attendances per annum, of which 4,106 would be for fracture. Including just the base case fracture types, this equated to 1,334 scans per year.

The EAG's base case assumed a weighted average cost and outcomes by fracture type. This was scaled up to the number of attendances per year to estimate the overall difference in cost and QALYs accrued to patients attending the 'typical' ED. The three fracture subtypes had different time horizons. By merging the three together the assumption was that costs and QALYs accrued after 6 months for wrist/hand and 12 months for ankle/foot were identical across all arms, in other words complete healing has taken place by this time. If any differences remained after these time horizons, then the analysis may underestimate the cost-effectiveness of AI-assisted diagnosis (i.e. overestimate the incremental cost-effectiveness, underestimate the incremental net health benefit).

Table 36: Base case distribution of fracture types

8.3.8. Cost of diagnosis & additional cost inputs

Cost of scans

Cost per scan was extracted from company RFIs where reported. Some companies operated volume-based pricing. The EAG's base case used a cost per scan based on 1,334 scans per annum. Base case prices are reported in **Error! Reference source not found.** and minimum and maximum prices are explored in Scenario analyses 3 and 4. Where no pricing data were supplied, the EAG inserted a notional cost per scan. The maximum economically justified price per scan for each software compared with unassisted diagnosis was also calculated.

Software	Cost per Scan	Notes
BoneView	£1.00	Notional cost
Rayvolve	£1.00	Notional cost
RBfracture		
TechCare Alert		
Unassisted	£0.00	By definition

Table 37 Cost per Scan (based on 1334 scans per annum)

Source: Company RFIs

Cost of A&E attendance

As the index presentation at A&E, and the X-ray, was common to all arms, the costs of these were excluded from the analysis. However, some cases (e.g. false negatives) were assumed to require an additional presentation after a period of time. This was costed on a mean cost of £149.04 (NHS Reference Costs 2022-23, code VB11Z: Emergency Medicine, no investigation, no significant treatment), and varied by $+/-10\%$ in a uniform distribution in the probabilistic analysis.

8.3.9. Approach to analysis

As there were multiple comparators, the EAG reports the incremental net health benefit of each technology compared with unassisted diagnosis at willingness to pay thresholds of £20,000 and £30,000 per QALY gained. This facilitates a fully incremental analysis as the option with the highest net health benefit is the option yielding an ICER at or below the threshold after taking into account dominated and extended dominated options; incremental comparisons between each technology can also be made by comparing the INHB directly. However, given the level of uncertainty and the rapid and approximate nature of the modelling for this assessment, the EAG cautions against comparing each AI software against each other, instead considering a 'class effect' for the software as a whole.

The EAG reports the results for each fracture location individually, followed by an overall weighted average for all three fracture subtypes based on case mix. This was multiplied up to show the expected impact on cost to the NHS and QALYs accrued to patients vs. unassisted for each software. Finally, the maximum economically justified price per scan was calculated as the cost per scan associated with an ICER of £20,000 per QALY and £30,000 per QALY.

8.3.10. Scenario analyses

The EAG planned to conduct scenario analyses on the use of the technology in different settings (e.g. ED vs UTC). However, the EAG considered that the grade of staff reading the radiograph was a more important determinant of the diagnostic accuracy than the setting, and any differences in resource use across the settings may largely be equal between all comparators. The EAG therefore conducted an optimistic and pessimistic scenario to represent different settings as described in Scenarios 1 & 2 below. Other scenarios are described below. An additional scenario is in Appendix D.

Scenarios 1 & 2: optimistic and pessimistic diagnostic accuracy

The EAG base case for this EVA used a naïve, unadjusted comparison of arms from two studies to inform the sensitivity and specificity of each technology. The EAG therefore explored an optimistic and pessimistic scenario, based on a review of all source studies (see Table 11 to Table 15). The optimistic scenario assumed the lowest sensitivity and specificity for unassisted diagnosis and highest for each technology, and the pessimistic the reverse (Table 38). Where a source suggested a lower or upper bound that was inside the EAG base case, the EAG base case was used as the estimate at the bound.

Table 38 Scenario analyses 1 & 2

Source: extracted from Table 11 to Table 16

Scenarios 3 & 4: cost per scan

Several companies price their software on the basis of annual volume. These scenarios explored a low volume (i.e. highest cost per scan) and high volume (lowest cost per scan) analysis for those technologies pricing based on volume (XXXXXXXXXXXXXXXX, Table 39).

Table 39: Scenarios 3&4 - cost per scan

Scenarios 5 & 6: Reduced time to interpret radiograph

Data on reduced reading time for X-rays are reported in Section 5.1.4 These studies generally reported time savings of between 7 and 13 seconds per scan assisted by the technology. For the purpose of this scenario analysis, the EAG assumed a notional 10 second reduction per Xray and subtracted the cost of this from the cost of the AI-assisted strategies under two scenarios: scenario 5 assumed the radiograph was read by a junior / trainee radiologist and scenario 6 by a consultant level radiologist (Table 40). The EAG noted advice from clinical experts that best practice use of the technology may lead to increases in reading time, though considered the lack of evidence for this, the EAG did not explore this scenario in the analysis.

Scenario 7: Health state utility for negative ankle & foot fractures.

The base case analysis for an ankle or foot fracture assumed that a patient without a fracture experienced an equal health state utility to a fracture, but only for two weeks before resolving (i.e. assuming a soft tissue injury which healed in two weeks). However, the EAG considered the health state utility to be lower than was plausible for such an injury and therefore lacking in face validity. The EAG therefore explored a scenario with a utility of 0.727, equivalent to EQ5D utility for a person with some mobility problems and some pain (overall profile 21121).

Scenario 8: Use of technology in all fractures.

The EAG base case assumed that the technology was only used in the three types of fractures considered in the analysis. However, the EAG considered it plausible that the software would be enabled for other fracture types. The EAG therefore conducted a scenario representing an additional cost associated with those other uses but assumed that zero benefit was gained from those reads. This therefore represents a pessimistic scenario of the broader use of the technology (Table 41).

Table 41: Casemix under scenario 8

Source: adapted from expert opinion

Scenario 9: Second read of all scans

The EAG base case used data on diagnostic accuracy as extracted from the two source studies. These comprised a single interpretation of the X-ray, although a second review of diagnoses was considered to be more reflective of real practice. To represent this, the EAG conducted a scenario where all scans were read a second time. It was assumed that the diagnostic accuracy of the second reader was the same as the first. As this was common to all arms, the cost was excluded from analysis.

8.4. Results from the economic modelling

8.4.1. Base case results

Overall, the majority of the AI-assisted diagnostic algorithms were associated with a positive incremental net health benefit compared with unassisted diagnosis at £20,000 and £30,000 thresholds, although 95% credibility intervals in most cases crossed zero, both for all fracture types and when considered together (Table 42 to Table 47). As noted previously, due to data limitations, the EAG advises against comparisons between the individual algorithms. The

minimum economically justified prices were somewhat above the proposed per-scan prices proposed by the companies. However, the EAG also cautions against use of these data to inform pricing decisions, as the modelling was only considered suitable for an indicative 'signal' of cost-effectiveness. More detailed analysis would be required to estimate a suitable maximum price per scan, along with fully incremental analysis to compare the benefits and costs of all the algorithms against one another.

Table 42: Base Case: Ankle/foot

Abbreviations: CI, confidence interval; INHB20k/INHB30k, incremental health benefit at willingness to pay threshold of £20/30k (versus unassisted); QALY, Quality Adjusted Life Year

Table 43: Base Case: Wrist/Hand

Abbreviations: CI, confidence interval; INHB20k/INHB30k, incremental health benefit at willingness to pay threshold of £20/30k (versus unassisted); QALY, Quality Adjusted Life Year

Table 44: Base Case: Hip

Abbreviations: CI, confidence interval; INHB20k/INHB30k, incremental health benefit at willingness to pay threshold of £20/30k (versus unassisted); QALY, Quality Adjusted Life Year

Table 45: Base Case: Overall

Abbreviations: CI, confidence interval; INHB20k/INHB30k, incremental health benefit at willingness to pay threshold of £20/30k (versus unassisted); QALY, Quality Adjusted Life Year

Table 46: Population level results (point estimates, based on 1334 patients scanned)

Abbreviations: INHB20k/INHB30k, incremental health benefit at willingness to pay threshold of £20/30k; QALY, Quality Adjusted Life Year

Table 47: Base Case Maximum Economically Justified Price

Abbreviations: ejp, economically justifiable price

8.4.2. Scenario analysis results

Results are summarised in Table 48. Scenario analyses suggested that the decision was sensitive to the optimistic and pessimistic scenarios (scenarios 1 & 2), implying there was much uncertainty in the data. However, the results suggested that there was the potential for AIassisted diagnosis of fracture to be cost-effective. Results were broadly insensitive to the low and high pricing scenarios for XXXXXXXXX (scenarios 3 & 4), when accounting for time taken to interpret X-rays (scenarios 5 & 6), adjusting for the health state utility of negative

ankle and foot fractures (scenario 7), use across all fractures rather than just the three locations analyses (scenario 8), and whether scans are read once or twice (scenario 9).

Whilst the scenario analyses of this EVA suggested that the only parameters to which the results were sensitive was the sensitivity and specificity of the diagnostic scans, the EAG advises caution in interpretation as more detailed modelling and analysis may lead to differing conclusions.

Table 48 Scenario analysis results (overall fractures)

Abbreviations: CI, confidence interval; INHB20k/30k, incremental health benefit at willingness to pay threshold of £20k/30k.

8.5. Summary and interpretation of the economic evidence

The early modelling for this EVA suggested that, at the proposed prices charged by the companies, AI assisted diagnosis had the potential to represent a value for money investment for the NHS at typical thresholds of £20,000 to £30,000 per QALY gained. However, this conclusion was considered highly uncertain at the present time. The EAG noted that the costeffectiveness appeared to be driven by reductions in costs rather than a gain in QALYs. The EAG cautions against using this analysis to compare one AI algorithm against another due to data limitations, and instead to consider whether AI-assisted diagnosis as a class would likely be of value. For example, the optimistic and pessimistic scenarios may not fully capture uncertainty and therefore may bias in favour or against technologies with only one source study. Future work, however, will require comparison of one algorithm against another to ensure the varying diagnostic accuracy of the algorithms is matched to their prices in a fully incremental analysis.

Scenario analysis concluded that the only parameters to which the decision was sensitive were the diagnostic accuracy of the algorithms and unassisted diagnosis, with the 'optimistic' and 'pessimistic' scenarios generating diverging conclusions. Other scenarios, including cost and time savings from AI-assisted diagnosis, low and high price-per-scan scenarios, and varying assumptions around health state utilities, use of AI in all fractures and including a second read of all X-rays did not materially affect the results.

9. EVIDENCE GAPS AND RESEARCH RECOMMENDATIONS

The EAG conducted a broad evidence review to identify the existing evidence base for the use of the technology to assist with the identification of fractures in emergency care settings. The EAG identified:

- 16 studies that evaluated the diagnostic accuracy of the technology
- 7 studies that reported X-ray reading time
- 0 studies that reported other service outcomes
- 0 studies that reported clinical outcomes for people with suspected fractures
- 0 economic evaluations of the technology.

With respect to the specific technologies eligible for consideration, the majority of the evidence evaluated BoneView (9 studies) and RBFracture (5 studies), with 2 studies available for both Rayvolve and TechCare Alert, and 0 studies available for qMSK. The availability of a head-tohead comparison²³ of three of the technologies this early in development of the technologies was notable, although this study lacked the availability of an unassisted arm for comparison purposes. As discussed throughout the report, the evidence base to date was limited in quality, with various risks of bias to the results as well as concerns about the generalisability of the evidence to clinical settings. Due to these issues, the EAG was unable to draw firm conclusions about the potential value of the technology, or identify reliable patterns in the results, such as according to reader experience, case mix, fracture subgroup, or population.

During the assessment, including during interpretation of the evidence base and feedback from clinicians and stakeholders to the assessment, the EAG identified complexities in developing evidence to evaluate interventions for use in people with suspected fractures and the services that treat them. One of the most significant of these considerations was that the target population of people with suspected fractures is highly heterogeneous, comprising of people with a broad range of demographics, type, mechanism and location of injury, and broader health considerations. As the diagnostic accuracy of X-ray and the broader care pathway will vary across populations (including the diagnosing clinicians, use of additional imaging modalities, use of precautionary tactics, and ongoing treatments), this means that the potential value of the technology will vary according to the population in which its used. The evaluation of the

technology within a representative population will therefore be key to deriving reliable estimates for outcomes. However, the target population is also not static, and will vary between types of urgent care settings (ED, UTC, MIU), across geographical areas in the UK, and will vary even within the same centre according to the day of the week, time of day, or season. Each centre will also vary in the local policies that they use to diagnose certain types of fractures and fractures in certain subpopulations, including their use of precautionary tactics but also including the typical staff available to read X-rays and the length of time until a definitive diagnosis is made. To inform understanding of the potential value of the technology, it will therefore be important to understand the way in which outcomes for the technology change according to differences in the population case mix, reader, and care pathway.

The economic analysis contained within this report represented a very top-level overview of the likely costs and consequences of adopting AI-assisted diagnosis of fracture within urgent care settings. Due to the resource and time constraints of this EVA, the EAG was unable to explore a large number of issues and nuances apparent in the data and a substantive evidence synthesis project of 12-18 months' duration would, in the opinion of the EAG, provide a solid appraisal of the evidence to fully inform a decision as to whether AI-assisted diagnosis of fracture represented a value for money investment in the NHS. Particular issues this should consider include:

• **Evaluation of the diagnostic accuracy, clinical and service outcomes associated with the technology within robust study designs within settings comparable with the likely use of the technology in clinical practice.**

This should include diagnostic randomised controlled trials and prospective, robustly sampled comparative studies (assisted vs. unassisted diagnosis) published in peerreviewed formats. Given that the technology would be expected to influence both clinical and service outcomes, future studies are needed to evaluate outcomes across both of these domains.

• **Formal network meta-analysis of studies and/or head-to-head studies**

A formal network meta-analysis was not considered feasible due to heterogeneity between studies (see section 5.2). However, further work is required to determine whether a less formal synthesis could be conducted, or else head-to-head studies are required for all relevant AI algorithms / software.

• **Studies to evaluate the factors that influence the value of the technology for identifying fractures**

This may include studies designed to explore change in outcomes according to key factors that would inform use of the technology, such as reader experience, case mix, and determinants of patient outcomes, such as patient age, frailty, and prevalence of health conditions affecting bone health. When a suitable evidence base is available, metaregression to explore factors that influence outcomes may help decision-makers to target the use of the technology in clinical practice.

• **Analysis of optimal cutoff points.**

This analysis made use of the stated sensitivity and specificity estimates from the literature. However, manufacturers of the algorithms (as well as the NHS) should consider the most cost-effective cut off score to maximise the efficiency of diagnosis. For example, some algorithms will generate a propensity score or probability of an X-ray being a fracture. An internal setting will determine what score and above is defined as a positive. Varying this score varies the sensitivity and specificity (from which the ROC curve can be generated). Connecting this to a decision model allows estimation of the optimal cutoff score for an algorithm (Laking et al 2006⁴⁷)

• **Greater exploration of the likely longer-term costs and consequences of true and false positive and negative diagnoses.**

This analysis relied on published studies to approximate long term costs and consequences of the four outcomes from a diagnosis. These varied in comparability, eg in terms of scope of resource use included and time horizon. A more comprehensive model breaking these items down in greater detail would enhance comparability between the different fracture types.

• **Impact of detecting multiple fractures.**

The economic analysis did not differentiate between a single and multiple fracture in a single patient. A particular use case and benefit of AI-assisted diagnosis could be in identifying a less obvious additional fracture which may be more likely to be missed by the reader. Further research into the benefit of this is warranted.

• **Second read of only positives or only negatives**

Scenario 9 of the economic analysis only considered a second read / review of all X-rays. An alternative approach is to review all positive or all negative diagnoses alone. Additional modelling would facilitate exploring the cost-effectiveness of this which may assist in enhancing the efficiency of the diagnostic X-ray service in clinical practice.

• **Formal assessment of study quality**

Consistent with methods for an EVA, formal quality assessment of the included studies was not conducted, and quality limitations of the included studies was conducted informally and discussed throughout the report. However, formal quality assessment of the current and future evidence base would be useful for characterising the strength of the evidence and identifying key weaknesses and their effect on outcomes. For the assessment of diagnostic accuracy studies, QUADAS-AI,⁴⁸ an extension to the original tool to account for the considerations specific to AI technologies, would be useful.

10. DISCUSSION

The EAG conducted a broad evidence review to identify the available evidence base for the value of AI as assistance to identifying fractures in urgent care settings. The assessment identified an emerging though limited evidence base for the technology, with meaningful gaps in evidence to inform decision-making on the use of the technology in clinical practice. Almost all of the evidence base identified evaluated the diagnostic accuracy of the technology for identifying fractures, though these analyses were largely not specific to emergency care settings or the staff that were anticipated to typically use the technology in clinical practice. There were also significant methodological limitations in the evidence base, which increased uncertainty in the findings. Aside from X-ray reading time, there was no evidence for the impact of the technology on service outcomes, such as the use of additional imaging, hospital appointments, and patient recalls, and no evidence for the health outcomes of people with suspected fractures. Overall, there was a paucity of evidence for determining the potential value of the technology for use within NHS settings.

In consideration of the limitations of the evidence base, the EAG tentatively concluded that there was early evidence that the technology may have value for reducing the risk of missed fractures but may not improve the avoidance of false positives. Due to uncertainty in the precise estimates reported by the studies, the EAG could not determine a reliable estimate for the reduction of missed fractures that could be avoided with the technology, though noted that the technology did not eradicate missed fractures entirely. Some studies, particularly those evaluating the accuracy of the technology in fracture types that were more difficult to identify, reported high rates of missed fractures that would be unacceptable in clinical practice. The implication of these findings was that while the technology may improve identification of fractures, its use would not remove the need for existing strategies used by urgent care settings to protect patients (such as further imaging, precautionary treatments, and fast turnaround times to definitive reports). As might be expected, there was less additional value of the technology when unassisted accuracy was already high, such as when used by senior staff and in fractures that were easier to diagnose. This would suggest that the technology may best be targeted towards the settings and populations where it may hold the greatest value; however, without evidence for the clinical and service outcomes that may be affected by using the technology, the EAG was unable to make this conclusion. For instance, the EAG considered it plausible that a small difference in sensitivity may nevertheless be meaningful if the additional fractures

identified would have otherwise resulted in significant health or resource implications. As noted in Section 9), further evidence is needed to explore this in order to inform decisions about if and how the technology could be used.

The current evidence base also did not allow for an understanding of how the potential evidence base might vary according to the target population. The majority of studies identified reported very few details about the study sample demographics, including the prevalence of people with frailty and health conditions that affect bone health. Very few studies reported outcomes specifically in children, where the identification of fractures can be particularly difficult. This wasn't notable in the results of the studies, however, where diagnostic accuracy both with and without the technology was not substantially different to results reported in adults alone. Given the limitations in the evidence base, the EAG considered that more evidence to evaluate the technology in children and across other key sub-populations would be important.

The economic analyses suggested that most of the AI assisted diagnostic algorithms were associated with a positive incremental net health benefit compared with unassisted diagnosis at NICE's lower and upper threshold band of £20,000 to £30,000 per QALY. The data were of insufficient quality to enable a robust comparison of one algorithm against another in a fully incremental analysis, which would be required to ensure the varying diagnostic accuracy of the different algorithms are matched to their prices, and to encourage a competitive market for the benefit of NHS patients. The results were largely insensitive to the different scenario analyses considered, except for diagnostic accuracy of the algorithms and unassisted diagnosis.

Overall, the results of this assessment must be considered within the context of the constraints of the EVA methods. Consistent with the aims of the EVA, the EAG adopted a pragmatic approach to the identification of evidence and exploration of this within its assessment. The EAG acknowledge a number of limitations to this approach, which included the use of single reviewer screening and data extraction, the broad inclusion criteria (allowing for the inclusion of lower quality evidence), and the lack of a formal quality assessment. The EAG was also unable to explore heterogeneity in the diagnostic accuracy results in more depth: while groupings of reader experience were made in order to aid interpretation of the results across studies, the EAG considered these to be unreliable, given difficulties in interpreting staff grades and experience as reported from publications of studies conducted in other countries. Given the variation in methods used across studies and the quality limitations of the evidence, further exploration of heterogeneity or re-grouping of studies may not have been meaningful, though

this is a limitation of the assessment. An exploratory economic analysis was developed, the objective of which was to establish whether there was a prima facie case for AI-assisted diagnosis of fracture to represent value for money for NHS patients (i.e. not to provide detailed guidance on and precise estimates of the cost-effectiveness of the different algorithms). It should therefore be considered an approximation placing plausible bounds on the likely costs and consequences of the algorithms and not a definitive estimate of the cost-effectiveness. A large number of gross assumptions were required to conduct the analysis within the assessment, for example the EAG was unable to consider the longer-term costs and consequences of false negatives and positives in anything but the most rudimentary manner. More detailed modelling in a full formal diagnostic assessment review is required to consider these issues and nuances, and how they are likely to impact the estimates of cost-effectiveness.

In conclusion, this assessment identified preliminary evidence that AI may have potential value for use within urgent care settings to aid with the identification of fractures. In order to inform a full evaluation of the technology, that could be used to inform decisions on routine commissioning, a significant body of further evidence is needed to establish the clinical, service and economic outcomes associated with the technology in settings relevant to urgent care within the NHS.

References

- 1. Hoppe BF, Rueckel J, Dikhtyar Y, et al. Implementing Artificial Intelligence for Emergency Radiology Impacts Physicians' Knowledge and Perception: A Prospective Pre- and Post-Analysis. *Investigative Radiology* 2024;59(5)
- 2. National Institute for Health and Care Excellence. Fractures (non-complex): assessment and management. NICE guideline [NG38]. Published: 17 February 2016. [Available from: https://www.nice.org.uk/guidance/ng38 accessed 1 July 2024.
- 3. NHS England. Diagnostic imaging reporting turnaround times 2023 [Available from: https://www.england.nhs.uk/long-read/diagnostic-imaging-reporting-turnaround-times/.
- 4. National Institute for Health and Care Excellence. Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment, 2023.
- 5. Kuo RYL, Harrison C, Curran TA, et al. Artificial Intelligence in Fracture Detection: A Systematic Review and Meta-Analysis. *Radiology* 2022;304(1):50-62. doi: https://dx.doi.org/10.1148/radiol.211785
- 6. Pauling C, Kanber B, Arthurs OJ, et al. Commercially available artificial intelligence tools for fracture detection: the evidence. *BJR|Open* 2024;6(1):tzad005. doi: 10.1093/bjro/tzad005
- 7. Radiobotics. RBFracture Improves the Diagnostic Accuracy of Emergency Care Professionals., 2021.
- 8. Bousson V, Attané G, Benoist N, et al. Artificial Intelligence for Detecting Acute Fractures in Patients Admitted to an Emergency Department: Real-Life Performance of Three Commercial Algorithms. *Academic Radiology* 2023;30(10):2118-39. doi: 10.1016/j.acra.2023.06.016
- 9. Cohen M, Puntonet J, Sanchez J, et al. Artificial intelligence vs. radiologist: accuracy of wrist fracture detection on radiographs. *European radiology* 2023;33(6):3974-83. doi: https://dx.doi.org/10.1007/s00330-022-09349-3
- 10. Meetschen M, Salhofer L, Beck N, et al. AI-Assisted X-ray Fracture Detection in Residency Training: Evaluation in Pediatric and Adult Trauma Patients. *Diagnostics* 2024;14(6):596. doi: https://dx.doi.org/10.3390/diagnostics14060596
- 11. Canoni-Meynet L, Verdot P, Danner A, et al. Added value of an artificial intelligence solution for fracture detection in the radiologist's daily trauma emergencies workflow. *Diagnostic and interventional imaging* 2022;103(12):594-600. doi: https://dx.doi.org/10.1016/j.diii.2022.06.004
- 12. Dell'Aria A, Tack D, Saddiki N, et al. Radiographic Detection of Post-Traumatic Bone Fractures: Contribution of Artificial Intelligence Software to the Analysis of Senior and Junior Radiologists. *Journal of the Belgian Society of Radiology* 2024 doi: 10.5334/jbsr.3574
- 13. Duron L, Ducarouge A, Gillibert A, et al. Assessment of an AI Aid in Detection of Adult Appendicular Skeletal Fractures by Emergency Physicians and Radiologists: A Multicenter Cross-sectional Diagnostic Study. *Radiology* 2021;300(1):120-29. doi: https://dx.doi.org/10.1148/radiol.2021203886
- 14. Guermazi A, Tannoury C, Kompel AJ, et al. Improving Radiographic Fracture Recognition Performance and Efficiency Using Artificial Intelligence. *Radiology* 2022;302(3):627-36. doi: https://dx.doi.org/10.1148/radiol.210937
- 15. Nguyen T, Maarek R, Hermann AL, et al. Assessment of an artificial intelligence aid for the detection of appendicular skeletal fractures in children and young adults by senior and junior radiologists. *Pediatric Radiology* 2022;52(11):2215-26. doi: https://dx.doi.org/10.1007/s00247-022-05496-3
- 16. Oppenheimer J, Luken S, Hamm B, et al. A Prospective Approach to Integration of AI Fracture Detection Software in Radiographs into Clinical Workflow. *Life (Basel, Switzerland)* 2023;13(1) doi: https://dx.doi.org/10.3390/life13010223
- 17. Bachmann R, Gunes G, Hangaard S, et al. Improving traumatic fracture detection on radiographs with artificial intelligence support: a multi-reader study. *BJR open* 2024;6(1):tzae011. doi: https://dx.doi.org/10.1093/bjro/tzae011
- 18. Automatic Hip Fracture Detection and Anatomical localisation with Deep Learning. Research Day, Region Zealand; 2023.
- 19. Ruitenbeek HC, Oei EHG, Schmahl BL, et al. Towards clinical implementation of an AIalgorithm for detection of cervical spine fractures on computed tomography. *European journal of radiology* 2024;173:111375. doi: https://dx.doi.org/10.1016/j.ejrad.2024.111375
- 20. Yogendra PM, Wei Goh AG, TYing YS, et al. Accuracy of radiologists and radiology residents in detection of paediatric appendicular fractures with
- and without the help of Artificial Intelligence. Unpublished (manuscript in preparation).
- 21. Fu T, Viswanathan V, Attia A, et al. Assessing the Potential of a Deep Learning Tool to Improve Fracture Detection by Radiologists and Emergency Physicians on Extremity Radiographs. *Academic radiology* 2024;31(5):1989-99. doi: https://dx.doi.org/10.1016/j.acra.2023.10.042
- 22. Parsy et al. MSK AI RETROSPECTIVE STUDY: Centre hospitalier de Valenciennes, 2020.
- 23. Bousson V, Attané G, Benoist N, et al. Artificial Intelligence for Detecting Acute Fractures in Patients Admitted to an Emergency Department: Real-Life Performance of Three Commercial Algorithms. *Acad Radiol* 2023;30(10):2118-39. doi: 10.1016/j.acra.2023.06.016 [published Online First: 20230718]
- 24. Dell'Aria A, Tack D, Saddiki N, et al. Radiographic Detection of Post-Traumatic Bone Fractures: Contribution of Artificial Intelligence Software to the Analysis of Senior and Junior Radiologists. *Journal of the Belgian Society of Radiology* 2024;108(1) doi: https://dx.doi.org/10.5334/jbsr.3574
- 25. Nguyen T, Maarek R, Hermann A-L, et al. Assessment of an artificial intelligence aid for the detection of appendicular skeletal fractures in children and young adults by senior and junior radiologists. *Pediatric Radiology* 2022;52(11):2215-26. doi: 10.1007/s00247-022- 05496-3
- 26. Bonde N et al. Hip fracture detection on conventional radiographs using deep learning artificial intelligence as a clinical support tool: A decrease of false negative diagnoses. Unpublished
- 27. EVALUATING THE IMPACT OF ARTIFICIAL INTELLIGENCE ON FRACTURE DETECTION: A MULTI-CENTER, MULTI-COUNTRY RANDOMIZED CONTROLLED
- CLINICAL TRIAL. RSNA 2024; 2024.
- 28. Radiobotics. TD 21-205 Retrospective CS Report RBfracture v.1 Rev.01 signed.
- 29. Chappell FM, Raab GM, Wardlaw JM. When are summary ROC curves appropriate for diagnostic meta-analyses? *Stat Med* 2009;28(21):2653-68. doi: 10.1002/sim.3631
- 30. The Royal College of Radiologists. Standards for the education and training of reporting practitioners in musculoskeletal plain radiographs 2022 [Available from: https://www.rcr.ac.uk/our-services/all-our-publications/clinical-radiologypublications/standards-for-the-education-and-training-of-reporting-practitioners-inmusculoskeletal-plain-radiographs/.
- 31. Rua T, Gidwani S, Malhotra B, et al. Cost-Effectiveness of Immediate Magnetic Resonance Imaging In the Management of Patients With Suspected Scaphoid Fracture: Results

From a Randomized Clinical Trial. *Value Health* 2020;23(11):1444-52. doi: 10.1016/j.jval.2020.05.020 [published Online First: 20200929]

- 32. Nwankwo H, Mason J, Costa ML, et al. Cost-utility analysis of cast compared to removable brace in the management of adult patients with ankle fractures. *Bone & Joint Open* 2022;3(6):455-62. doi: 10.1302/2633-1462.36.Bjo-2022-0036
- 33. Low YL, Finkelstein E. Cost-Effective Analysis of Dual-Energy Computed Tomography for the Diagnosis of Occult Hip Fractures Among Older Adults. *Value Health* 2021;24(12):1754-62. doi: 10.1016/j.jval.2021.06.005 [published Online First: 20210805]
- 34. Judge A, Javaid MK, Leal J. Models of care for the delivery of secondary fracture prevention after hip fracture: a health service cost, clinical outcomes and cost-effectiveness study within a region of England: NIHR Journals Library, 2016.
- 35. Ward JL, Azzopardi PS, Francis KL, et al. Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet* 2021;398(10311):1593-618. doi: 10.1016/S0140-6736(21)01546-4
- 36. Cieza A, Causey K, Kamenov K, et al. Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet* 2020;396(10267):2006-17. doi: 10.1016/S0140-6736(20)32340-0
- 37. Wu A-M, Bisignano C, James SL, et al. Global, regional, and national burden of bone fractures in 204 countries and territories, $1990&\#x2013;2019$: a systematic analysis from the Global Burden of Disease Study 2019. *The Lancet Healthy Longevity* 2021;2(9):e580-e92. doi: 10.1016/S2666-7568(21)00172-0
- 38. Chen C, Lin J-R, Zhang Y, et al. A systematic analysis on global epidemiology and burden of foot fracture over three decades. *Chinese Journal of Traumatology* 2024 doi: https://doi.org/10.1016/j.cjtee.2024.03.001
- 39. Baji P, Barbosa EC, Heaslip V, et al. Use of removable support boot versus cast for early mobilisation after ankle fracture surgery: cost-effectiveness analysis and qualitative findings of the Ankle Recovery Trial (ART). *BMJ Open* 2024;14(1):e073542. doi: 10.1136/bmjopen-2023-073542 [published Online First: 20240111]
- 40. Howell M, Lawson A, Naylor J, et al. Surgical plating versus closed reduction for fractures in the distal radius in older patients: a cost-effectiveness analysis from the hospital perspective. *ANZ J Surg* 2022;92(12):3311-18. doi: 10.1111/ans.18134 [published Online First: 20221105]
- 41. Hannemann PF, Essers BA, Schots JP, et al. Functional outcome and cost-effectiveness of pulsed electromagnetic fields in the treatment of acute scaphoid fractures: a cost-utility analysis. *BMC Musculoskelet Disord* 2015;16:84. doi: 10.1186/s12891-015-0541-2 [published Online First: 20150411]
- 42. Faccioli N, Santi E, Foti G, et al. Cost-effectiveness of introducing cone-beam computed tomography (CBCT) in the management of complex phalangeal fractures: economic simulation. *Musculoskelet Surg* 2022;106(2):169-77. doi: 10.1007/s12306-020-00687-3 [published Online First: 20201119]
- 43. Rua T, Malhotra B, Vijayanathan S, et al. Clinical and cost implications of using immediate MRI in the management of patients with a suspected scaphoid fracture and negative radiographs results from the SMaRT trial. *Bone Joint J* 2019;101-b(8):984-94. doi: 10.1302/0301-620x.101b8.Bjj-2018-1590.R1
- 44. Abimanyi-Ochom J, Watts JJ, Borgström F, et al. Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS). *Osteoporos Int* 2015;26(6):1781-90. doi: 10.1007/s00198-015-3088-z [published Online First: 20150320]
- 45. Keating JF, Grant A, Masson M, et al. Randomized comparison of reduction and fixation, bipolar hemiarthroplasty, and total hip arthroplasty. Treatment of displaced intracapsular hip fractures in healthy older patients. *J Bone Joint Surg Am* 2006;88(2):249-60. doi: 10.2106/jbjs.E.00215
- 46. Jonsson B, Kanis J, Dawson A, et al. Effect and offset of effect of treatments for hip fracture on health outcomes. *Osteoporos Int* 1999;10(3):193-9. doi: 10.1007/s001980050215
- 47. Laking G, Lord J, Fischer A. The economics of diagnosis. *Health Econ* 2006;15(10):1109- 20. doi: 10.1002/hec.1114
- 48. Sounderajah V, Ashrafian H, Rose S, et al. A quality assessment tool for artificial intelligence-centered diagnostic test accuracy studies: QUADAS-AI. *Nature Medicine* 2021;27(10):1663-65. doi: 10.1038/s41591-021-01517-0

Appendix A – Search strategies

Search strategies

Embase <1974 to 2024 June 25>

- 1 exp artificial intelligence/ 106277
- 2 exp *Machine Learning/ 206084
- 3 ("deep learning" or "artificial neural network*" or "deep neural network*" or "convolutional neural network*").ti,ab,kf. 118642
- 4 ((machine or transfer or algorithmic) adj2 Learning).ti,ab,kf.144555

5 ("AI" or "comput* Intelligence" or "comput* reasoning" or "machine Intelligence" or "artificial intelligence").ti,ab,kf. 114372

6 ("neural networks" or "natural language processing" or 'llm*1 or large language model*').ti,ab,kf. 79238

7 ("reinforcement learning" or "deep belief network*" or "recurrent neural network*" or "feedforward neural network*").ti,ab,kf. 14879

8 "feed forward neural network*".ti,ab,kf. 1080

9 ("boltzmann machine*" or "long short-term memory" or "gated recurrent unit*" or "rectified linear unit*" or autoencoder or "auto-encoder" or backpropagation or "multilayer perceptron" or "multi-layer perceptron" or convnet or "convolutional learning").ti,ab,kf. 18309

10 or/1-9 461984

11 "diagnostic imaging".ti,ab,kf. 30009

12 exp diagnostic imaging/ 275165

13 exp X-Ray/ 89150

14 (radiograph* or radiologist or radiogram or XR or x-ray or "radiological image*" or photographic or "digital image*" or radiology or roentgenogram or roentgenograph or "Rontgen ray*" or x-rayed or "x ray*").ti,ab,kf. 977193

15 11 or 12 or 13 or 14 1247290

16 exp fracture/ 370018

17 ((fractur* or break* or fissur* or shatter* or crack* or splinter* or broken or dislocat* or luxat* or subluxat* or trauma or disjoint* or displace*) adj2 (bone* or joint* or skeletal or skeleton)).ti,ab,kf. 41115

18 ((spiral or avulsion or compression or greenstick or "green stick" or intraarticular or "intra articular" or pathologic or stress or comminuted or dislocation or hairline or "hair line" or impacted or longitudinal or oblique or transverse or pathological or insufficiency or vertebral or elbow* or arm* or leg* or ankle* or wrist* or finger* or toe* or pelvis or pelvic or hip* or shoulder* or spine or spinal or chest or rib* or knee* or hand* or foot or feet or face or facial or microfracture or fatigue or macroscopic or periprosthetic) adj2 (fractur* or break* or fissur* or shatter* or crack* or splinter* or broken or injur*)).ti,ab,kf. 264517

19 (("long bone" or "short bone" or "flat bone" or sesamoid or irregular or epiphysis or physis or metaphysis or diaphysis or tubercle or epicondyle or complete or incomplete or displaced or non-displaced or "non displaced" or stable or unstable or simple or closed or segmental or bowing or buckle or oblique or complex or non-complex or "non complex" or salter-harris or "salter harris" or Lisfranc or "distal radial" or "growth plate" or suspect*) adj2 (fractur* or break* or fissur* or shatter* or crack* or splinter* or broken or injur*)).ti,ab,kf. 49830

20 or/16-19 544797

21 10 and 15 and 20 1020

22 (AZmed or "AZ med" or "AZ medical" or AZmedical or Gleamer or Radiobotics or Qure or Milvue).af. 206

23 (Rayvolve or Boneview or "Bone view" or RBfracture or "RB fracture" or qMSK or qXR or qER or "TechCare Alert" or "Tech Care Alert" or SmartUrgence or "Smart Urgence").af. 128

24 21 or 22 or 23 1307

25 limit 24 to (dd=20200701-20240626 or rd=20200701-20240626 or dc=20200701- 20240626) 920

Ovid MEDLINE(R) ALL <1946 to June 25, 2024>

1 exp artificial intelligence/ 200607

2 exp Machine Learning/ 70860

3 ("deep learning" or "artificial neural network*" or "deep neural network*" or "convolutional neural network*").ti,ab,kf. 103348

4 ((machine or transfer or algorithmic) adj2 Learning).ti,ab,kf.125093

5 ("AI" or "comput* Intelligence" or "comput* reasoning" or "machine Intelligence" or "artificial intelligence").ti,ab,kf. 91108
6 ("neural networks" or "natural language processing" or 'llm*1 or large language model*').ti,ab,kf. 66698

7 ("reinforcement learning" or "deep belief network*" or "recurrent neural network*" or "feedforward neural network*").ti,ab,kf. 13366

8 "feed forward neural network*".ti,ab,kf. 839

9 ("boltzmann machine*" or "long short-term memory" or "gated recurrent unit*" or "rectified linear unit*" or autoencoder or "auto-encoder" or backpropagation or "multilayer perceptron" or "multi-layer perceptron" or convnet or "convolutional learning").ti,ab,kf. 16957

10 or/1-9 387820

11 "diagnostic imaging".ti,ab,kf. 21096

12 exp diagnostic imaging/ 2977377

13 X-Rays/ 32478

14 (radiograph* or radiologist or radiogram or XR or x-ray or "radiological image*" or photographic or "digital image*" or radiology or roentgenogram or roentgenograph or "Rontgen ray*" or x-rayed or "x ray*").ti,ab,kf. 823590

15 11 or 12 or 13 or 14 3516695

16 exp fractures, bone/ 215213

17 ((fractur* or break* or fissur* or shatter* or crack* or splinter* or broken or dislocat* or luxat* or subluxat* or trauma or disjoint* or displace*) adj2 (bone* or joint* or skeletal or skeleton)).ti,ab,kf. 31804

18 ((spiral or avulsion or compression or greenstick or "green stick" or intraarticular or "intra articular" or pathologic or stress or comminuted or dislocation or hairline or "hair line" or impacted or longitudinal or oblique or transverse or pathological or insufficiency or vertebral or arm* or leg* or ankle* or wrist* or elbow* or finger* or toe* or pelvis or pelvic or hip* or shoulder* or spine or spinal or chest or rib* or knee* or hand* or foot or feet or face or facial or microfracture or fatigue or macroscopic or periprosthetic) adj2 (fractur* or break* or fissur* or shatter* or crack* or splinter* or broken or injur*)).ti,ab,kf. 211184

19 (("long bone" or "short bone" or "flat bone" or sesamoid or irregular or epiphysis or physis or metaphysis or diaphysis or tubercle or epicondyle or complete or incomplete or displaced or non-displaced or "non displaced" or stable or unstable or simple or closed or segmental or bowing or buckle or oblique or complex or non-complex or "non complex" or salter-harris or "salter harris" or Lisfranc or "distal radial" or "growth plate" or suspect*) adj2 (fractur* or break* or fissur* or shatter* or crack* or splinter* or broken or injur*)).ti,ab,kf. 42244

20 16 or 17 or 18 or 19 384408

21 10 and 15 and 20 885

22 (AZmed or "AZ med" or "AZ medical" or AZmedical or Gleamer or Radiobotics or Qure or Milvue).af. 146

23 (Rayvolve or Boneview or "Bone view" or RBfracture or "RB fracture" or qMSK or qXR or qER or "TechCare Alert" or "Tech Care Alert" or "Smart Urgence" or SmartUrgence).af. 69

24 21 or 22 or 23 1068

25 limit 24 to (ed=20200701-20240626 or dt=20200701-20240626) 745

The Cochrane Library

Date Run: 26/06/2024 16:12:22

ID SearchHits

#1 MeSH descriptor: [Artificial Intelligence] explode all trees 3198

#2 MeSH descriptor: [Machine Learning] explode all trees 986

#3 ("deep learning" or artificial NEXT neural NEXT network* or deep NEXT neural NEXT network* or convolutional NEXT neural NEXT network*):ti,ab,kw 1772

#4 ((machine or transfer or algorithmic) near/3 Learning):ti,ab,kw 3228

#5 ("AI" or comput* NEXT Intelligence or comput* NEXT reasoning or "machine Intelligence" or "artificial intelligence"):ti,ab,kw 7206

#6 ("neural networks" or "natural language processing" or llm*1 or large NEXT language NEXT model*):ti,ab,kw 1291

#7 ("reinforcement learning" or deep NEXT belief NEXT network* or recurrent NEXT neural NEXT network* or feedforward NEXT neural NEXT network*):ti,ab,kw 306

#8 feed NEXT forward NEXT neural NEXT network*:ti,ab,kw 23

#9 (boltzmann NEXT machine* or "long short-term memory" or gated NEXT recurrent NEXT unit* or rectified NEXT linear NEXT unit* or autoencoder or "auto-encoder" or backpropagation or "multilayer perceptron" or "multi-layer perceptron" or convnet or "convolutional learning"):ti,ab,kw 189

#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 13275

#11 "diagnostic imaging":ti,ab,kw 44309

#12 MeSH descriptor: [Diagnostic Imaging] explode all trees 69276

#13 MeSH descriptor: [X-Rays] explode all trees 106

#14 (radiograph* or radiologist or radiogram or XR or x-ray or radiological NEXT image* or photographic or digital NEXT image* or radiology or roentgenogram or roentgenograph or Rontgen NEXT ray* or x-rayed or "x ray" or "x rayed"):ti,ab,kw 59279

#15 #11 or #12 or #13 or #14 116068

#16 MeSH descriptor: [Fractures, Bone] explode all trees 9509

#17 ((fractur* or break* or fissur* or shatter* or crack* or splinter* or broken or dislocat* or luxat* or subluxat* or trauma or disjoint* or displace*) near/3 (bone* or joint* or skeletal or skeleton)):ti,ab,kw 7070

#18 ((spiral or avulsion or compression or greenstick or "green stick" or intraarticular or "intra articular" or pathologic or stress or comminuted or dislocation or hairline or "hair line" or impacted or longitudinal or oblique or transverse or pathological or insufficiency or vertebral or elbow* or arm* or leg* or ankle* or wrist* or finger* or toe* or pelvis or pelvic or hip* or shoulder* or spine or spinal or chest or rib* or knee* or hand* or foot or feet or face or facial or microfracture or fatigue or macroscopic or periprosthetic) near/2 (fractur* or break* or fissur* or shatter* or crack* or splinter* or broken or injur*)):ti,ab,kw 25565

#19 ("long bone" or "short bone" or "flat bone" or sesamoid or irregular or epiphysis or physis or metaphysis or diaphysis or tubercle or epicondyle or complete or incomplete or displaced or non-displaced or "non displaced" or stable or unstable or simple or closed or segmental or bowing or buckle or oblique or complex or non-complex or "non complex" or salter-harris or "salter harris" or Lisfranc or "distal radial" or "growth plate" or suspect*) near/2 (fractur* or break* or fissur* or shatter* or crack* or splinter* or broken or injur*)):ti,ab,kw 3290

#20 #16 or #17 or #18 or #19 32637

#21 #10 and #15 and #20 53

#22 (AZmed or "AZ med" or "AZ medical" or AZmedical or Gleamer or Radiobotics or Qure or Milvue) 50

#23 (Rayvolve or Boneview or "Bone view" or RBfracture or "RB fracture" or qMSK or qXR or qER or "TechCare Alert" or "Tech Care Alert" or SmartUrgence or "Smart Urgence") 24

#24 #21 or #22 or #23 125

Limit to 2020-2024 57

Web of Science

#1 TS=("boltzmann machine*" or "long short-term memory" or "gated recurrent unit*" or "rectified linear unit*" or autoencoder or "auto-encoder" or backpropagation or "multilayer perceptron" or "multi-layer perceptron" or convnet or "convolutional learning") 109,743

 $#2$ TS=("feed forward neural network*") $7,197$

#3 TS=("reinforcement learning" or "deep belief network*" or "recurrent neural network*" or "feedforward neural network*") $\frac{102,380}{200}$

#4 TS=("neural networks" or "natural language processing" or llm*1 or "large language model*") 413,303

#5 TS=(("AI" or "comput* Intelligence" or "comput* reasoning" or "machine Intelligence" or "artificial intelligence")) 263,773

#6 TS=(((machine or transfer or algorithmic) N2 Learning)) 218

#7 TS=("deep learning" or "artificial neural network*" or "deep neural network*" or "convolutional neural network*") 503,397

#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 1,003,767

#9 TS=(("long bone" or "short bone" or "flat bone" or sesamoid or irregular or epiphysis or physis or metaphysis or diaphysis or tubercle or epicondyle or complete or incomplete or displaced or non-displaced or "non displaced" or stable or unstable or simple or closed or segmental or bowing or buckle or oblique or "distal radial" or Lisfranc or complex or noncomplex or "non complex" or salter-harris or "salter harris" or "growth plate" or suspect*) N2 (crack* or splinter* or broken or injur*)) 406

#10 TS=(("long bone" or "short bone" or "flat bone" or sesamoid or irregular or epiphysis or physis or metaphysis or diaphysis or tubercle or epicondyle or complete or incomplete or displaced or non-displaced or "non displaced" or stable or unstable or simple or closed or segmental or bowing or buckle or oblique or complex or non-complex or "non complex" or salter-harris or "salter harris" or Lisfranc or "distal radial" or "growth plate" or suspect*) N2 (fractur* or break* or fissur* or shatter*)) 467

#11 TS=((spiral or avulsion or compression or greenstick or "green stick" or intraarticular or "intra articular" or pathologic or stress or comminuted or dislocation or hairline or "hair line" or impacted or longitudinal or oblique or transverse or pathological or insufficiency or vertebral or arm* or leg* or ankle* or wrist* or pelvis or pelvic or hip* or shoulder* or spine or spinal or chest or rib* or knee* or hand* or elbow* or finger* or toe* or foot or feet or face or facial or microfracture or fatigue or macroscopic or periprosthetic) N2 (crack* or splinter* or broken or injur*)) 416

#12 TS=((spiral or avulsion or compression or greenstick or "green stick" or intraarticular or "intra articular" or pathologic or stress or comminuted or dislocation or hairline or "hair line" or impacted or longitudinal or oblique or transverse or pathological or insufficiency or vertebral or arm* or leg* or ankle* or wrist* or pelvis or pelvic or hip* or shoulder* or spine or spinal or chest or rib* or knee* or hand* or elbow* or foot or feet or finger* or toe* or face or facial or microfracture or fatigue or macroscopic or periprosthetic) N2 (fractur* or break* or fissur* or shatter*)) 427

#13 TS=((fractur* or break* or fissur* or shatter* or crack* or splinter* or broken or dislocat* or luxat* or subluxat* or trauma or disjoint* or displace*) N2 (bone* or joint* or skeletal or skeleton)

73

#14 #9 OR #10 OR #11 OR #12 OR #13 1,259

#15 #8 AND #14 $\frac{7}{ }$

#16 ALL=(AZmed or "AZ med" or "AZ medical" or AZmedical or Gleamer or Radiobotics or Qure or Milvue) and the contract of the contract of

#17 ALL=(Rayvolve or Boneview or "Bone view" or RBfracture or "RB fracture" or qMSK or qXR or qER or "TechCare Alert" or "Tech Care Alert" or SmartUrgence or "Smart Urgence") 107

#18 #15 OR #16 OR #17 and 2020 or 2021 or 2022 or 2023 or 2024 (Publication Years) 167

Appendix B – PRISMA diagrams

*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).

**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

Source: Page MJ, et al. BMJ 2021;372:n71. doi: 10.1136/bmj.n71.

This work is licensed under CC BY 4.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/

Appendix C – Excluded studies

Table 49: List of excluded English-language publications studies from company lists, with reasons

Table 50: List of excluded full-text publications from EAG evidence search, with reasons

Appendix D – Additional Scenario Analyses

This appendix contains additional analysis requested by NICE and specialist committee members to provide further information prior to the appraisal committee meeting.

Some companies stated that their software was associated with setup costs. Feedback from an SCM suggested that there are also costs incurred within the NHS to support set up of a new technology, specifically NHS IT time and fees from PACS providers to ensure the new technology works correctly and does not cause any issues with the existing radiology workflow. These may be up to £50,000 per site. The EAG therefore presented an analysis adding a notional one-off set up fee of £50,000, and conducted a threshold analysis stating the maximum set-up fee for AI detection to be cost-effective. This is equivalent to the incremental net monetary benefit at a site (rather than individual patient) level.

Similarly, the EAG assumed a notional five-year life for the software. That is, the fixed costs were apportioned on a per-scan basis over five years. The EAG conducted a scenario here assuming they are apportioned over two years.

Method

Aggregate figures reported in Table 46 correspond to one year's use of the algorithms. These are multiplied by five to approximate a five year lifespan of the software. The INHB and INMB are calculated including a £50,000 one-off set up cost.

Results

The results are broadly insensitive to a £50,000 setup cost: most of the interventions are associated with a cost saving in excess of this when considered over a 5 year lifetime of the algorithm (Table 51). The EAG noted that even over a one year lifespan of the algorithm, a £50,000 will still not offset the savings associated use of most of the algorithms. The maximum cost of installation for the algorithms to still represent value for money is equal to £50,000 plus the INMB at the chosen threshold. For example, the maximum cost for installation, assuming a threshold of £20,000 / QALY for BoneView is £4.240m (£4.190m + £50k). The EAG noted that this is likely far above a plausible estimate of the cost for this.

Abbreviations: INHB20k/INHB30k, incremental health benefit at willingness to pay threshold of £20/30k; INMB20k/INMB£30k incremental net monetary benefit at each threshold; QALY, Quality Adjusted Life Year

Artificial intelligence software to help detect fractures on X-rays in urgent care

External Assessment Report (EAR) and economic model - Comments

External Assessment Report - Comments

Artificial intelligence software to help detect fractures on X-rays in urgent care

External Assessment Report (EAR) and economic model - Comments